Anti-ICOS×Anti-CXCR4 multispecific protein
A multispecific binding protein targeting ICOS and CXCR4 addresses the limitations of existing therapeutics by regulating Tfh and B cell interactions, effectively reducing IgM and IgG production and modulating cytokine secretion for treating autoimmune diseases.
Patent Information
- Application Number
- PCT/EP2026/064249
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current therapeutics for autoimmune diseases, such as Abatacept, are limited in effectively regulating the interaction between T follicular helper (Tfh) cells and B cells, leading to dysregulated responses and hyperactivated autoreactive B cells, necessitating a need for compositions and methods to treat and/or prevent immune and autoimmune diseases.
A multispecific binding protein comprising a first antigen-binding domain (ABD) that binds to the extracellular domain of ICOS and a second ABD that binds to CXCR4, along with nucleic acids, vectors, and cells expressing these proteins, to modulate the interaction between Tfh and B cells.
The multispecific binding protein effectively regulates Tfh cell responses, reducing IgM and IgG production, and modulating cytokine secretion, thereby providing a therapeutic approach for immune and autoimmune diseases.
Smart Images

Figure IMGF000016_0001_TABLE 
Figure IMGF000017_0001_TABLE 
Figure IMGF000017_0002_TABLE
Abstract
Description
[0001] PCT application
[0002] Sanofi
[0003] Our Ref.: 589-391 PCT
[0004] ANTI-IC0SxANTI-CXCR4 MULTISPECIFIC PROTEIN
[0005] FIELD OF THE INVENTION
[0006] The present invention relates to a multispecific binding protein comprising a first antigenbinding domain (ABD) specifically binding to the extracellular domain of ICOS and a second ABD specifically binding to the extracellular domain of CXCR4. Also disclosed herein is the use of such multi specific binding protein in medicine.
[0007] BACKGROUND OF THE INVENTION
[0008] Germinal centers (GCs) form after immunization or infection to provide a niche where antigen specific activated B cells undergo class switching, affinity maturation, memory and plasma cell differentiation. Mature GCs contain GC B cells, T follicular helper (Tfh) cells, tingible body macrophages, a network of follicular dendritic and reticular cells expressing CXCL12, the ligand for CXCR4, which is responsible for the polarization of the GCs into the light zone (LZ) and dark zone (DZ).
[0009] Tfh cells are a subset of CD4 Th cells necessary for follicular B cell maturation into memory (Bmem) and long-lived plasma cells (PCs). Tfh cells promote B cell proliferation and affinity maturation within the GC providing stimuli such as CD40 ligand, and IL-21. Tfh cells also promote B cell isotype switching appropriate to the invading pathogen by secretion of IL-4 and IFN-y. Weinstein JS, et cd.. 2014. J Immunol. 192(7): 3166-79. Tfh differentiation is a multistage process. Upon priming by DCs, CD4+T cells start to differentiate into Tfh and migrate to the T-B border, and interact with antigen-specific B cells in an ICOSTCOSL and peptide:MHC dependent manner. The additional signals from cognate B cells drive further GC-Tfh differentiation and the formation of GCs. It has been shown that the magnitude of the Tfh cell response depends on the amount of antigen and correlates with the magnitude of the GC B cell response. In addition, maintenance of the Tfh cell phenotype requires sustained antigenic stimulation by GC B cells.
[0010] Within the GCs, antigen-specific B cell clones interact with Tfh cells, and are cyclically selected and expanded based on antigen affinity. Successful delivery of Tfh cell-derived help to the B cells in the GCs results in the formation of high-affinity, cl ass- switched antibody-secreting cells as well as long-lived memory B cells. Foster WS, etal., 2022. Cell Rep Med. 3(12): 100845.Therefore, in the GCs, Tfh cell differentiation and maintenance depends on B cells, and GC B and plasma cells (PCs) depend on Tfh cells. These feedback loops are crucial for proper regulation of humoral immunity.
[0011] Spatial segregation of GC B cells into the two zones DZ and LZ relies on the chemokine receptor CXCR4. While early models attributed high and low levels of CXCR4 expression to a dark and light zone phenotype respectively, recent studies show a unimodal and markedly heterogeneous CXCR4 expression profile of GC B cells, indicating a continuum of intermediate CXCR4 levels rather than a binary dark or light zone phenotype (Weber, TS, 2017. BioRxiv).
[0012] Dysregulated Tfh cell responses are causative for many autoimmune disorders, where Tfh cells often exert a pathogenic role. Moreover, many autoimmune diseases are associated with hyperactivated or autoreactive B cells. Therapeutics for autoimmune diseases are limited. An example is Abatacept, a soluble fusion protein linking the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc portion of human immunoglobulin G1 (IgGl). The CTLA4 domain of Abatacept binds to CD80 / CD86 with a higher affinity than to CD28, effectively preventing its activation. Abatacept is effective in limiting Tfh activation but also antagonizes Tregs. There is a long felt need in the art for compositions and methods useful for regulating the interaction between Tfh and B cells to treat and / or prevent immune and autoimmune diseases.
[0013] SUMMARY OF THE INVENTION
[0014] In a first aspect, the present invention relates to a multispecific binding protein comprising:
[0015] (a) a first antigen-binding domain (ABD) specifically binding to an extracellular domain of ICOS; and
[0016] (b) a second ABD specifically binding to an extracellular domain of CXCR4.
[0017] In a second aspect, the present invention relates to a nucleic acid or nucleic acids encoding the multispecific binding protein of the first aspect.
[0018] In a third aspect, the present invention relates to a vector comprising the nucleic acid or nucleic acids of the second aspect.
[0019] In a fourth aspect, the present invention relates to a cell comprising the nucleic acid or nucleic acids of the second aspect or the vector of the third aspect.
[0020] In a fifth aspect, the present invention relates to a pharmaceutical composition comprising the multi specific binding protein of the first aspect, the nucleic acid or nucleic acids of the secondaspect, the vector of the third aspect, or the cell of the fourth aspect, and at least one pharmaceutically acceptable carrier, diluent, excipient and / or adjuvant.
[0021] In a sixth aspect, the present invention relates to a multispecific binding protein according to the first aspect, a nucleic acid or nucleic acids according to the second aspect, a vector according to the third aspect, a cell according to the fourth aspect, or a pharmaceutical composition according to the fifth aspect for use in medicine.
[0022] In a seventh aspect, the present invention relates to a multispecific binding protein according to the first aspect, a nucleic acid or nucleic acids according to the second aspect, a vector according to the third aspect, a cell according to the fourth aspect, or a pharmaceutical composition according to the fifth aspect for use in a method of treating and / or preventing an immune disease, preferably an auto-immune disease in a subject.
[0023] In an eighth aspect, the present invention relates to a mono or multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH:
[0024] (i) comprising CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3; and / or (ii) having at least 80% amino acid identity to SEQ ID NO: 3.
[0025] DETAILED DESCRIPTION OF THE INVENTION
[0026] Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0027] Preferably, the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (TUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Klbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland) and as described in "Pharmaceutical Substances: Syntheses, Patents, Applications" by Axel Kleemann and Jurgen Engel, Thieme Medical Publishing, 1999; the "Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", edited by Susan Budavari et al., CRC Press, 1996, and the United States Pharmacopeia-25 / National Formulary-20, published by the United States Pharmcopeial Convention, Inc., Rockville Md., 2001.In the following, the elements of the present invention will be described. These elements are listed with specific embodiments, however, it should be understood that they might be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments should not be construed to limit the present invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments, which combine the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, any permutations and combinations of all described elements in this application should be considered disclosed by the description of the present application unless the context indicates otherwise. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
[0028] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", are to be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. In preferred embodiments, "comprise" can mean "consist of'. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents, unless the content clearly dictates otherwise. Whenever the conjunction "and / or" is used herein, the preferred embodiment is "and", unless indicated otherwise.
[0029] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.) are hereby incorporated by reference in their entirety.
[0030] Brief description of the drawings
[0031] Figure 1: Effect of the bispecific binding protein on IgM (A) and IgG (B) production.
[0032] The levels of IgM and IgG were measured in the cell supernatants of Tfh / B cell co-cultures after 10 days of exposure to the binding protein indicated in the legend. To minimize the impact of donor-to-donor variability, IgM and IgG levels are expressed as ratio of values from binding protein-treated versus blank wells.
[0033] Figure 2: Effect of the bispecific binding protein on IgM (A, C) and IgG (B, D) production versus the monospecific binding protein alone or in combo. The experiments were performed as described for Figure 1. A) IgM levels of donor 783920; B) IgG levels of donor 783920; C) IgM levels of donor 783921; D) IgG levels of donor 783921.Figure 3: IgM and IgG secretion need Tfh-coculture. The experiments were performed as described for Figure 1, with the addition that IgM and IgG were measured also in the cell supernatants of not-Tfh / B cell co-cultures. A) IgM levels of donor 783920; B) IgG levels of donor 783920; C) IgM levels of donor 783921; D) IgG levels of donor 783921.
[0034] Figure 4: Effect of the bispecific binding protein on the abundancy of T cells, B cells, plasmablasts, and plasma cells. A), C), E), and G) values were obtained from the samples of donor 783920; B), D), F), and H) values were obtained from the samples of donor 783921.
[0035] Figure 5: Combined IgG responses obtained in the MIMIC Recall assay. : Cells were treated with Fluzone and bispecific binding proteins obtained by either Spy Tag / Spy Catcher bioconjugation and / or genetic fusion: (I) aRSV-SpyTag / aRSV-SpyCatcher, (II) alCOS-SpyTag / aRSV-SpyCatcher, (III) aCXCR4-SpyTag / aRSV-SpyCatcher, (IV) alCOS-SpyTag / aCXCR4-SpyCatcher, (V) aICOS-aALB-aCXCR4, or medium (control wells).
[0036] Figure 6: Cytokine production following incubation of PBMCs with alCOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein. Shown is the average fold change (compared to media control) of IFNy (A), IL-6 (B), TNFa (C), GM-CSF (D), IL-17A (E), and IL-10 (F) after culture of PBMCs from Sjogren's syndrome donors or healthy donors with alCOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein at a concentration of 100 nM (the highest concentration tested). Cytokines were measured in supernatants after an overnight culture.
[0037] Figure 7: Distribution of the different marker and bright field microscopy images of cells exposed to aICOS-aALB-aCXCR4 (SEQ ID NO: 9) or to an RSV control ISDV. The B cells formed contacts with the SLB using the uropod (Uro) and cell body. The cell body attached through LFA-l-ICAM-1 interactions, whereas the uropod attached through the anti-MHC class II and the bispecific aICOS-aALB-aCXCR4 compound. Interestingly, aICOS-aALB-aCXCR4 (SEQ ID NO: 9) binding segregated from the anti-MHC class II and tended to increase the area of anti-MHC II signal compared to the pattern of tight clustering of anti-MHC II seen in the non-binding RSV control.
[0038] Tables
[0039] Table 1: Overview and explanation of the SEQ ID NOs: 1-74 referred to in the application The amino acid and nucleic acid sequences of SEQ ID NOs: 1-74 are shown in Table 4.SEQ Type Short Name Description
[0040] ID NO:
[0041] 1 aa CXCR4 Uniprot P61073
[0042] 2 aa ICOS Uniprot Q9Y6W8
[0043] 3, aa, na aCXCR4 Anti-CXCR4 VHH
[0044] 44
[0045] 4, aa, na alCOS Anti-ICOS VHH
[0046] 45
[0047] 5, aa, na aALB Anti-ALB VHH
[0048] 46
[0049] 6, aa, na aCXCR4-aALB Anti-CXCR4 VHH with a half-life increasing moiety 47
[0050] 7, aa, na aCXCR4-SpyTag Anti-CXCR4 VHH with SpyTag sequence at its C-terminus 48
[0051] 8, aa, na alCOS-SpyTag Anti-ICOS VHH with SpyTag sequence at its C-terminus 49
[0052] 9, aa, na aICOS-aALB-aCXCR4 Anti-ICOS x anti-CXCR4 multispecific binding protein with 50 a half-life increasing moiety (aALB)
[0053] 10, aa, na aRSV-aALB Anti-RSV VHH with a half-life increasing moiety
[0054] 51
[0055] 11, aa, na aRSV-SpyTag Anti-RSV VHH with SpyTag sequence at its C-terminus 52
[0056] 12, aa, na aRSV-SpyCatcher Anti-RSV VHH with SpyCatcher sequence at its C-terminus 53
[0057] 13, aa, na aCXCR4 CDR1 Residues 26-35 of SEQ ID NO: 3
[0058] 54
[0059] 14, aa, na aCXCR4 CDR2 Residues 50-60 of SEQ ID NO: 3
[0060] 55
[0061] 15, aa, na aCXCR4 CDR3 Residues 100-115 of SEQ ID NO: 3
[0062] 56
[0063] 16, aa, na aCXCR4 FR1 Residues 1-25 of SEQ ID NO: 3
[0064] 57
[0065] 17, aa, na aCXCR4 FR2 Residues 36-49 of SEQ ID NO: 3
[0066] 58
[0067] 18, aa, na aCXCR4 FR3 Residues 61-99 of SEQ ID NO: 3
[0068] 59
[0069] 19, aa, na aCXCR4 FR4 Residues 116-126 of SEQ ID NO: 3
[0070] 60
[0071] 20, aa, na alCOS CDR1 Residues 26-35 of SEQ ID NO: 4
[0072] 61
[0073] 21, aa, na alCOS CDR2 Residues 50-58 of SEQ ID NO: 4
[0074] 62
[0075] 22, aa, na alCOS CDR3 Residues 98-108 of SEQ ID NO: 4
[0076] 63
[0077] 23, aa, na alCOS FR1 Residues 1-25 of SEQ ID NO: 4
[0078] 64
[0079] 24, aa, na alCOS FR2 Residues 36-49 of SEQ ID NO: 4
[0080] 65
[0081] 25, aa, na alCOS FR3 Residues 59-97 of SEQ ID NO: 4
[0082] 66
[0083] 26, aa, na alCOS FR4 Residues 109-119 of SEQ ID NO: 4
[0084]
[0085] 27, aa, na aALB CDR1 Residues 26-35 of SEQ ID NO: 5 68
[0086] 28, aa, na aALB CDR2 Residues 50-59 of SEQ ID NO: 5 69
[0087] 29, aa, na aALB CDR3 Residues 99-104 of SEQ ID NO: 5 70
[0088] 30, aa, na aALB FR1 Residues 1-25 of SEQ ID NO: 5 71
[0089] 31, aa, na aALB FR2 Residues 36-49 of SEQ ID NO: 5 72
[0090] 32, aa, na aALB FR3 Residues 60-98 of SEQ ID NO: 5 73
[0091] 33, aa, na aALB FR4 Residues 105-115 of SEQ ID NO: 5 74
[0092] 34 aa 5GS GGGGS
[0093] 35 aa 7GS SGGSGGS
[0094] 36 aa 8GS GGGGSGGS
[0095] 37 aa 10GS (G4S)2
[0096] 38 aa 15GS (G4S)3
[0097] 39 aa 20GS (G4S)4
[0098] 40 aa 25GS (G4S)5
[0099] 41 aa 30GS (G4S)e
[0100] 42 aa 35GS (G4S)7
[0101]
[0102] 43 aa 40GS (G4S)8
[0103] Legend: aa: amino acid; na: nucleic acid
[0104] Table 2. CDRs and FRs sequences of exemplary ABDs
[0105] Antibody Region Sequence aCXCR4 CDR1 IMGT: 26-33 of SEQ ID NO: 3;
[0106] SEQ ID Kabat: 31-35 of SEQ ID NO: 3;
[0107] NO: 3 Chothia: 26-32 of SEQ ID NO: 3 aCXCR4 CDR2 IMGT: 51-59 of SEQ ID NO: 3;
[0108] SEQ ID Kabat: 50-67 of SEQ ID NO: 3;
[0109] NO: 3 Chothia: 52-58 of SEQ ID NO: 3 aCXCR4 CDR3 IMGT: 98-115 of SEQ ID NO: 3;
[0110] SEQ ID Kabat: 100-115 of SEQ ID NO: 3;
[0111] NO: 3 Chothia: 100-115 of SEQ ID NO: 3 alCOS CDR1 IMGT: 26-33 of SEQ ID NO: 4;
[0112] SEQ ID Kabat: 31-35 of SEQ ID NO: 4;
[0113] NO: 4 Chothia: 26-32 of SEQ ID NO: 4 alCOS CDR2 IMGT: 51-57 of SEQ ID NO: 4;
[0114] SEQ ID Kabat: 50-65 of SEQ ID NO: 4;
[0115] NO: 4 Chothia: 52-56 of SEQ ID NO: 4 alCOS CDR3 IMGT: 96-108 of SEQ ID NO: 4;
[0116] SEQ ID Kabat: 98-108 of SEQ ID NO: 4;
[0117] NO: 4 Chothia: 98-108 of SEQ ID NO: 4 aALB CDR1 IMGT: 26-33 of SEQ ID NO: 5;
[0118] SEQ ID Kabat: 31-35 of SEQ ID NO: 5;
[0119] NO: 5 Chothia: 26-32 of SEQ ID NO: 5 aALB CDR2 IMGT: 51-58 of SEQ ID NO: 5;
[0120] SEQ ID Kabat: 50-66 of SEQ ID NO: 5;
[0121]
[0122] NO: 5 Chothia: 52-57 of SEQ ID NO: 5aALB CDR3 IMGT: 97-104 of SEQ ID NO: 5;
[0123] SEQ ID Kabat: 99-104 of SEQ ID NO: 5;
[0124] NO: 5 Chothia: 99-104 of SEQ ID NO: 5
[0125] aCXCR4 FR1 to FR4 IMGT: FR1: 1-25; FR2: 34-50, FR3: 60-97, FR4: 116-126 SEQ ID Kabat: FR1: 1-30; FR2: 36-49, FR3: 68-99, FR4: 116-126 NO: 3 Chothia: FR1: 1-25; FR2: 33-51, FR3: 59-99, FR4: 116-126 alCOS FR1 to FR4 IMGT: FR1: 1-25; FR2: 34-50, FR3: 58-95, FR4: 109-119 SEQ ID Kabat: FR1: 1-30; FR2: 36-49, FR3: 66-97, FR4: 109-119 NO: 4 Chothia: FR1: 1-25; FR2: 33-51, FR3: 57-97, FR4: 109-119 aALB FR1 to FR4 IMGT: FR1: 1 -25; FR2: 34-50, FR3: 59-96, FR4: 105-115 SEQ ID Kabat: FR1: 1 - 30; FR2: 36-49, FR3: 67-98, FR4: 105-115
[0126]
[0127] NO: 5 Chothia: FR1: 1 -25; FR2: 33-51, FR3: 58-98, FR4: 105-115
[0128] Table 3 : Hallmark Residues in the ISVDs described herein
[0129] Position Human VH3 Hallmark Residues
[0130] 11 L, V; predominantly L L, S, V, M, W, F, T, Q, E, A, R, G, K, Y, N, P, I;
[0131] preferably L
[0132] 37 V, I, F; usually V F(1), Y, V, L, A, H, S, I, W, C, N, G, D, T, P, preferably F(1)orY
[0133] 44(8) G E(3), Q(3), G(2), D, A, K, R, L, P, S, V, H, T, N, W, M, I;
[0134] preferably G(2), E(3)or Q(3);most preferably G(2)or Q(3)45(8) L L(2), R(3), P, H, F, G, Q, S, E, T, Y, C, I, D, V; preferably L(2)or R(3)
[0135] 47(8) W,Y F(’), L<9 or W(2)G, I, S, A, V, M, R, Y, E, P, T, C, H, K,
[0136] Q, N, D; preferably W(2), L(1)or F(1)
[0137] 83 R or K; usually R R, K(5), T, E(5), Q, N, S, I, V, G, M, L, A, D, Y, H;
[0138] preferably K or R; most preferably K
[0139] 84 A, T, D; predominantly A P(5), S, H, L, A, V, I, T, F, D, R, Y, N, Q, G, E; preferably P
[0140] 103 W W(4), R(6), G, S, K, A, M, Y, L, F, T, N, V, Q, P(6), E, C;
[0141] preferably W
[0142] 104 G G, A, S, T, D, P, N, E, C, L; preferably G
[0143] 108 L, M or T; predominantly L Q, L'7;i. R, P, E, K, S, T, M, A, H; preferably Q or L'7;iNotes:
[0144] (1 ) In particular, but not exclusively, in combination with KERE or KQRE at positions 43-46.
[0145] (2) Usually as GLEW at positions 44-47.
[0146] (3) Usually as KERE or KQRE at positions 43-46, e.g. as KEREL, KEREF, KQREL, KQREF, KEREG, KQREW or KQREG at positions 43-47. Alternatively, also sequences such as TERE (for example TEREL), TQRE (for example TQREL), KECE (for example KECEL or KECER), KQCE (for example KQCEL), RERE (for example REREG), RQRE (for example RQREL, RQREF or RQREW), QERE (for example QEREG), QQRE, (for example QQREW, QQREL or QQREF), KGRE (for example KGREG), KDRE (for example KDREV) are possible. Some other possible, but less preferred sequences include for example DECKL and NVCEL.
[0147] (4) With both GLEW at positions 44-47 and KERE or KQRE at positions 43-46.
[0148] (5) Often as KP or EP at positions 83-84 of naturally occurring VHH domains.
[0149] (6) In particular, but not exclusively, in combination with GLEW at positions 44-47.
[0150] (7) With the proviso that when positions 44-47 are GLEW, position 108 is always Q in (non-humanized) VHH sequences that also contain a W at 103.
[0151] (8) The GLEW group also contains GLEW-like sequences at positions 44-47, such as for example GVEW, EPEW,
[0152]
[0153] GLER, DQEW, DLEW, GIEW, ELEW, GPEW, EWLP, GPER, GLER and ELEW.Table 4: Sequence List
[0154] SEQ Type Short Name Sequence
[0155] ID NO:
[0156] 1 aa CXCR4 MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFL PTIYSIIFLTGIVGNGLVILVMGYQKKLRSMTDKYRLHLSV ADLLFVITLPFWAVDAVANWYFGNFLCKAVHVIYTVNLYS SVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIP ALLLTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHI MVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKTTVILILAF FACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAF FHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGK RGGHSSVSTESESSSFHSS
[0157] 2 aa ICOS MKSGLWYFFLFCLRIKVLTGEINGSANYEMFIFHNGGVQIL CKYPDIVQQFKMQLLKGGQILCDLTKTKGSGNTVSIKSLKF CHSQLSNNSVSFFLYNLDHSHANYYFCNLSIFDPPPFKVTL TGGYLHIYESQLCCQLKFWLPIGCAAFWVCILGCILICWLT KKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL
[0158] 3 aa aCXCR4 EVQLVESGGGVVQPGGSLRLSCAASGRTFNSYAMAWFRQ APGKEREFVAAIRWSGGRATKYADSVKGRFTISKDNAKNT VYLQMNSLRPEDTALYYCATQTYYRSGLASTRDFDSWGQ GTLVTVSS
[0159] 4 aa alCOS EVQLVESGGGLVQPGGSLRLSCAASGSIFRINVMGWYRQA PGKQRELVAATATGGSTTYADSVKGRFTISSDNAKNTVYL QMNSLRPEDTAVYYCNAVDGGGLYVMDYWGQGTLVTVS
[0160] S
[0161] 5 aa aALB EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQ APGKGPEWVSSISGSGSDTLYADSVKGRFTISRDNSKNTLY LQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS
[0162] 6 aa aCXCR4-aALB EVQLVESGGGVVQPGGSLRLSCAASGRTFNSYAMAWFRQ APGKEREFVAAIRWSGGRATKYADSVKGRFTISKDNAKNT VYLQMNSLRPEDTALYYCATQTYYRSGLASTRDFDSWGQ GTLVTVSSGGGGSGGGSEVQLVESGGGVVQPGGSLRLSCA ASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADS VKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSR SSQGTLVTVSS
[0163] 7 aa aCXCR4- EVQLVESGGGVVQPGGSLRLSCAASGRTFNSYAMAWFRQ SpyTag APGKEREFVAAIRWSGGRATKYADSVKGRFTISKDNAKNT VYLQMNSLRPEDTALYYCATQTYYRSGLASTRDFDSWGQ GTLVTVSSGGGGSGGGSRGVPHIVMVDAYKRYKAAADYK DHDGDYKDHDIDYKDDDDKGAAHHHHHH
[0164] 8 aa alCOS-SpyTag EVQLVESGGGLVQPGGSLRLSCAASGSIFRINVMGWYRQA PGKQRELVAATATGGSTTYADSVKGRFTISSDNAKNTVYL QMNSLRPEDTAVYYCNAVDGGGLYVMDYWGQGTLVTVS SGGGGSGGGSRGVPHIVMVDAYKRYKAAADYKDHDGDY KDHDIDYKDDDDKGAAHHHHHH
[0165] 9 aa alCOS-aALB- EVQLVESGGGLVQPGGSLRLSCAASGSIFRINVMGWYRQA aCXCR4 PGKQRELVAATATGGSTTYADSVKGRFTISSDNAKNTVYL QMNSLRPEDTAVYYCNAVDGGGLYVMDYWGQGTLVTVS SGGGGSGGGSEVQLVESGGGVVQPGGSLRLSCAASGFTFR SFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSVKGRFTI SRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLV
[0166]
[0167] TVSSGGGGSGGGSEVQLVESGGGVVQPGGSLRLSCAASGRTFNSYAMAWFRQAPGKEREFVAAIRWSGGRATKYADSVK GRFTISKDNAKNTVYLQMNSLRPEDTALYYCATQTYYRSG LASTRDFDSWGQGTLVTVSS
[0168] aa aRSV-aALB EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQA PGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYL QMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRG TLVTVSSGGGGSGGGSEVQLVESGGGVVQPGGSLRLSCAA SGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSV KGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRS SQGTLVTVSS
[0169] aa aRSV-SpyTag EVQLVESGGGVVQAGGSLSISCAASGGSLSNYVLGWFRQA PGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYL QMNSLAPDDTALYYCGAGTPLNPGAYIYDWSYDYWGRG TLVTVSSGGGGSGGGSRGVPHIVMVDAYKRYKAAADYKD HDGDYKDHDIDYKDDDDKGAAHHHHHH
[0170] aa aRSV- EVQLVESGGGVVQAGGSLSISCAASGGSLSNYVLGWFRQA SpyCatcher PGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYL QMNSLAPDDTALYYCGAGTPLNPGAYIYDWSYDYWGRG TLVTVSSGGGGSGGGSVTTLSGLSGEQGPSGDMTTEEDSA THIKFSKRDEDGRELAGATMELRDSSGKTISTWISDGHVKD FYLYPGKYTFVETAAPDGYEVATPIEFTVNEDGQVTVDGE ATEGDAHTAAADYKDHDGDYKDHDIDYKDDDDKGAAHH HHHH
[0171] aa aCXCR4 CDR1 GRTFNSYAMA
[0172] aa aCXCR4 CDR2 AIRWSGGRATK
[0173] aa aCXCR4 CDR3 QTYYRSGLASTRDFDS
[0174] aa aCXCR4 FR1 EVQLVESGGGVVQPGGSLRLSCAAS
[0175] aa aCXCR4 FR2 WFRQAPGKEREFVA
[0176] aa aCXCR4 FR3 YADSVKGRFTISKDNAKNTVYLQMNSLRPEDTALYYCAT aa aCXCR4 FR4 WGQGTLVTVSS
[0177] aa alCOS CDR1 GSIFRINVMG
[0178] aa alCOS CDR2 ATATGGSTT
[0179] aa alCOS CDR3 VDGGGLYVMDY
[0180] aa alCOS FR1 EVQLVESGGGLVQPGGSLRLSCAAS
[0181] aa alCOS FR2 WYRQAPGKQRELVA
[0182] aa alCOS FR3 YADSVKGRFTISSDNAKNTVYLQMNSLRPEDTAVYYCNA aa alCOS FR4 WGQGTLVTVSS
[0183] aa aALB CDR1 GFTFRSFGMS
[0184] aa aALB CDR2 SISGSGSDTL
[0185] aa aALB CDR3 GGSLSR
[0186] aa aALB FR1 EVQLVESGGGVVQPGGSLRLSCAAS
[0187] aa aALB FR2 WVRQAPGKGPEWVS
[0188] aa aALB FR3 YADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTI aa aALB FR4 SSQGTLVTVSS
[0189] aa 5GS GGGGS
[0190] aa 7GS SGGSGGS
[0191] aa 8GS GGGGSGGS
[0192] aa 10GS GGGGSGGGGS
[0193] aa 15GS GGGGSGGGGSGGGGS
[0194] aa 20GS GGGGSGGGGSGGGGSGGGGS
[0195] aa 25GS GGGGSGGGGSGGGGSGGGGSGGGGS
[0196] aa 30GS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
[0197]
[0198] aa 35GS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSaa 40GS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGG GS
[0199] na aCXCR4 GAGGTGCAATTGGTGGAGTCTGGGGGTGGTGTTGTTCAG CCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGT CGTACCTTTAATAGCTATGCAATGGCATGGTTTCGTCAG GCACCGGGTAAAGAACGTGAATTTGTTGCAGCAATTCGT TGGAGCGGTGGTCGTGCAACCAAATATGCAGATAGCGT TAAAGGTCGCTTTACCATTAGCAAAGATAATGCGAAAA ACACCGTTTACCTGCAGATGAATAGTCTGCGTCCTGAAG ATACCGCATTGTATTATTGTGCAACCCAGACCTATTATC GTAGCGGTCTGGCAAGCACCCGTGATTTTGATAGCTGGG GTCAGGGAACCCTGGTCACCGTCTCCTCA
[0200] na alCOS GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCA GCCTGGAGGATCTCTTAGACTCTCCTGTGCAGCCTCTGG AAGCATCTTCCGTATCAATGTCATGGGCTGGTACCGCCA GGCTCCAGGGAAGCAGCGCGAGTTGGTCGCGGCTACTG CTACTGGTGGTAGCACAACCTATGCAGACTCCGTGAAGG GCCGATTCACCATCTCCAGCGACAACGCCAAGAACACG GTGTATCTGCAAATGAACAGCCTGAGACCTGAGGACAC GGCCGTCTATTACTGTAATGCAGTCGACGGTGGTGGCTT ATATGTGATGGACTACTGGGGCCAGGGTACGCTGGTCAC CGTCTCCTCA
[0201] na aALB GAGGTGCAATTGGTGGAGTCTGGGGGAGGTGTTGTTCA GCCGGGTGGCTCCCTGCGTCTGTCTTGCGCAGCTTCTGG TTTCACCTTTCGTAGCTTCGGTATGAGCTGGGTACGTCA GGCTCCAGGCAAAGGCCCGGAGTGGGTCTCTAGCATCA GCGGTTCTGGCTCTGATACCCTCTACGCGGATTCCGTGA AAGGTCGCTTCACCATTAGCCGTGACAACAGCAAAAAC ACCCTGTACCTGCAGATGAACTCTCTGCGCCCGGAAGAC ACTGCCCTGTACTACTGTACGATCGGTGGTTCCCTGTCTC GCTCCTCTCAGGGGACCCTGGTCACCGTCTCCTCA
[0202] na aCXCR4-aALB GAGGTGCAATTGGTGGAGTCTGGGGGTGGTGTTGTTCAG CCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGT CGTACCTTTAATAGCTATGCAATGGCATGGTTTCGTCAG GCACCGGGTAAAGAACGTGAATTTGTTGCAGCAATTCGT TGGAGCGGTGGTCGTGCAACCAAATATGCAGATAGCGT TAAAGGTCGCTTTACCATTAGCAAAGATAATGCGAAAA ACACCGTTTACCTGCAGATGAATAGTCTGCGTCCTGAAG ATACCGCATTGTATTATTGTGCAACCCAGACCTATTATC GTAGCGGTCTGGCAAGCACCCGTGATTTTGATAGCTGGG GTCAGGGAACCCTGGTCACGGTCTCCTCCGGAGGCGGT GGGTCAGGAGGTGGCTCAGAGGTACAACTAGTGGAGTC TGGTGGAGGCGTAGTCCAACCCGGTGGTAGTCTGCGCCT TAGCTGCGCTGCAAGTGGATTCACGTTTAGGTCTTTTGG TATGAGTTGGGTCAGACAGGCTCCCGGCAAGGGACCAG AGTGGGTCTCCTCAATTTCTGGATCTGGATCAGATACAT TGTACGCAGACTCTGTGAAAGGTAGGTTCACGATTTCTA GGGACAACTCAAAGAATACGCTGTACTTACAAATGAAC TCATTACGTCCCGAGGATACAGCCTTGTATTATTGCACA ATCGGCGGCAGTCTATCCAGATCATCCCAAGGAACCCTG GTCACCGTCTCCTCA
[0203] na aCXCR4- GAGGTGCAATTGGTGGAGTCTGGGGGTGGTGTTGTTCAG SpyTag CCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGCGGT
[0204] CGTACCTTTAATAGCTATGCAATGGCATGGTTTCGTCAG
[0205]
[0206] GCACCGGGTAAAGAACGTGAATTTGTTGCAGCAATTCGTTGGAGCGGTGGTCGTGCAACCAAATATGCAGATAGCGT TAAAGGTCGCTTTACCATTAGCAAAGATAATGCGAAAA ACACCGTTTACCTGCAGATGAATAGTCTGCGTCCTGAAG ATACCGCATTGTATTATTGTGCAACCCAGACCTATTATC GTAGCGGTCTGGCAAGCACCCGTGATTTTGATAGCTGGG GTCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGAGGTG GCTCTGGTGGCGGATCACGTGGTGTGCCACACATCGTGA TGGTGGACGCGTATAAACGTTACAAAGCTGCCGCAGAC TATAAAGATCATGATGGCGATTATAAAGATCACGATATT GATTATAAAGACGATGATGACAAAGGGGCGGCTCATCA CCATCACCATCAC
[0207] na alCOS-SpyTag GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCA GCCTGGAGGATCTCTTAGACTCTCCTGTGCAGCCTCTGG AAGCATCTTCCGTATCAATGTCATGGGCTGGTACCGCCA GGCTCCAGGGAAGCAGCGCGAGTTGGTCGCGGCTACTG CTACTGGTGGTAGCACAACCTATGCAGACTCCGTGAAGG GCCGATTCACCATCTCCAGCGACAACGCCAAGAACACG GTGTATCTGCAAATGAACAGCCTGAGACCTGAGGACAC GGCCGTCTATTACTGTAATGCAGTCGACGGTGGTGGCTT ATATGTGATGGACTACTGGGGCCAGGGTACGCTGGTCAC CGTCTCCTCAGGTGGAGGTGGCTCTGGTGGCGGATCACG TGGTGTGCCACACATCGTGATGGTGGACGCGTATAAACG TTACAAAGCTGCCGCAGACTATAAAGATCATGATGGCG ATTATAAAGATCACGATATTGATTATAAAGACGATGATG ACAAAGGGGCGGCTCATCACCATCACCATCAC
[0208] na alCOS-aALB- GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCA aCXCR4 GCCTGGAGGATCTCTTAGACTCTCCTGTGCAGCCTCTGG AAGCATCTTCCGTATCAATGTCATGGGCTGGTACCGCCA GGCTCCAGGGAAGCAGCGCGAGTTGGTCGCGGCTACTG CTACTGGTGGTAGCACAACCTATGCAGACTCCGTGAAGG GCCGATTCACCATCTCCAGCGACAACGCCAAGAACACG GTGTATCTGCAAATGAACAGCCTGAGACCTGAGGACAC GGCCGTCTATTACTGTAATGCAGTCGACGGTGGTGGCTT ATATGTGATGGACTACTGGGGCCAGGGTACCCTGGTCAC GGTCTCCTCCGGAGGCGGTGGCTCAGGCGGTGGATCCG AGGTGCAGTTGGTGGAGTCTGGTGGAGGCGTAGTCCAA CCCGGTGGTAGTCTGCGCCTTAGCTGCGCTGCAAGTGGA TTCACGTTTAGGTCTTTTGGTATGAGTTGGGTCAGACAG GCTCCCGGCAAGGGACCAGAGTGGGTCTCCTCAATTTCT GGATCTGGATCAGATACATTGTACGCAGACTCTGTGAAA GGTAGGTTCACGATTTCTAGGGACAACTCAAAGAATAC GCTGTACTTACAAATGAACTCATTACGTCCCGAGGATAC AGCCTTGTATTATTGCACAATCGGCGGCAGTCTATCCAG ATCATCCCAAGGAACCCTGGTCACGGTCTCGAGCGGAG GCGGTGGGTCAGGAGGTGGCTCAGAGGTACAACTAGTG GAGTCTGGGGGTGGTGTTGTTCAGCCTGGTGGTAGCCTG CGTCTGAGCTGTGCAGCAAGCGGTCGTACCTTTAATAGC TATGCAATGGCATGGTTTCGTCAGGCACCGGGTAAAGA ACGTGAATTTGTTGCAGCAATTCGTTGGAGCGGTGGTCG TGCAACCAAATATGCAGATAGCGTTAAAGGTCGCTTTAC CATTAGCAAAGATAATGCGAAAAACACCGTTTACCTGC AGATGAATAGTCTGCGTCCTGAAGATACCGCATTGTATT ATTGTGCAACCCAGACCTATTATCGTAGCGGTCTGGCAA GCACCCGTGATTTTGATAGCTGGGGTCAGGGAACCCTGG
[0209]
[0210] TCACCGTCTCCTCAna aRSV-aALB GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCA GGCTGGGGGCTCTCTGAGCATCTCCTGTGCAGCCTCGGG AGGCTCTTTAAGTAACTATGTGTTGGGATGGTTCCGCCA GGCTCCAGGCAAGGAGCGTGAGTTTGTGGCGGCTATTA ACTGGCGTGGTGATATCACAATCGGTCCACCTAACGTGG AGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAAC ACGGGGTATCTGCAAATGAACAGCCTGGCACCTGATGA CACGGCCGTTTATTACTGTGGAGCTGGGACCCCCTTGAA TCCTGGTGCTTACATCTATGATTGGAGTTACGACTACTG GGGCCGGGGGACCCTGGTCACGGTCTCCTCCGGAGGCG GTGGGTCAGGAGGTGGCTCAGAGGTACAACTAGTGGAG TCTGGTGGAGGCGTAGTCCAACCCGGTGGTAGTCTGCGC CTTAGCTGCGCTGCAAGTGGATTCACGTTTAGGTCTTTT GGTATGAGTTGGGTCAGACAGGCTCCCGGCAAGGGACC AGAGTGGGTCTCCTCAATTTCTGGATCTGGATCAGATAC ATTGTACGCAGACTCTGTGAAAGGTAGGTTCACGATTTC TAGGGACAACTCAAAGAATACGCTGTACTTACAAATGA ACTCATTACGTCCCGAGGATACAGCCTTGTATTATTGCA CAATCGGCGGCAGTCTATCCAGATCATCCCAAGGAACC CTGGTCACCGTCTCCTCA
[0211] na aRSV-SpyTag GAGGTGCAATTGGTGGAGTCTGGGGGAGGAGTGGTGCA GGCTGGGGGCTCTCTGAGCATCTCCTGTGCAGCCTCGGG AGGCTCTTTAAGTAACTATGTGTTGGGATGGTTCCGCCA GGCTCCAGGCAAGGAGCGTGAGTTTGTGGCGGCTATTA ACTGGCGTGGTGATATCACAATCGGTCCACCTAACGTGG AGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAAC ACGGGGTATCTGCAAATGAACAGCCTGGCACCTGATGA CACGGCCTTGTATTACTGTGGAGCTGGGACCCCCTTGAA TCCTGGTGCTTACATCTATGATTGGAGTTACGACTACTG GGGCCGGGGGACCCTGGTCACCGTCTCCTCAGGTGGAG GTGGCTCTGGTGGCGGATCACGTGGTGTGCCACACATCG TGATGGTGGACGCGTATAAACGTTACAAAGCTGCCGCA GACTATAAAGATCATGATGGCGATTATAAAGATCACGA TATTGATTATAAAGACGATGATGACAAAGGGGCGGCTC ATCACCATCACCATCAC
[0212] na aRSV- GAGGTGCAATTGGTGGAGTCTGGGGGAGGAGTGGTGCA SpyCatcher GGCTGGGGGCTCTCTGAGCATCTCCTGTGCAGCCTCGGG AGGCTCTTTAAGTAACTATGTGTTGGGATGGTTCCGCCA GGCTCCAGGCAAGGAGCGTGAGTTTGTGGCGGCTATTA ACTGGCGTGGTGATATCACAATCGGTCCACCTAACGTGG AGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAAC ACGGGGTATCTGCAAATGAACAGCCTGGCACCTGATGA CACGGCCTTGTATTACTGTGGAGCTGGGACCCCCTTGAA TCCTGGTGCTTACATCTATGATTGGAGTTACGACTACTG GGGCCGGGGGACCCTGGTCACCGTCTCCTCAGGTGGAG GTGGATCAGGTGGAGGATCAGTGACCACACTTTCTGGAC TGAGTGGAGAGCAAGGACCTAGCGGCGACATGACCACC GAGGAGGACAGCGCCACCCACATCAAGTTCAGCAAGAG AGACGAGGACGGCAGAGAGCTGGCCGGCGCCACCATGG AGCTGAGAGACAGCAGCGGCAAGACCATCAGCACCTGG ATCAGCGACGGCCACGTGAAGGACTTCTACCTGTACCCC GGCAAGTACACCTTCGTGGAGACCGCCGCCCCCGACGG CTACGAGGTGGCCACCCCCATCGAGTTCACCGTGAACG AGGACGGCCAGGTGACAGTGGACGGCGAGGCCACCGAG
[0213]
[0214] GGCGATGCCCACACCGCTGCCGCAGACTATAAAGATCATGATGGCGATTATAAAGATCATGACATTGATTATAAAGA CGATGACGATAAAGGGGCGGCTCATCACCATCACCATC AC
[0215] 54 na aCXCR4 CDR1 GGTCGTACCTTTAATAGCTATGCAATGGCA
[0216] 55 na aCXCR4 CDR2 GCAATTCGTTGGAGCGGTGGTCGTGCAACCAAA
[0217] 56 na aCXCR4 CDR3 CAGACCTATTATCGTAGCGGTCTGGCAAGCACCCGTGAT TTTGATAGC
[0218] 57 na aCXCR4 FR1 GAGGTGCAATTGGTGGAGTCTGGGGGTGGTGTTGTTCAG CCTGGTGGTAGCCTGCGTCTGAGCTGTGCAGCAAGC
[0219] 58 na aCXCR4 FR2 TGGTTTCGTCAGGCACCGGGTAAAGAACGTGAATTTGTT GCA
[0220] 59 na aCXCR4 FR3 TATGCAGATAGCGTTAAAGGTCGCTTTACCATTAGCAAA GATAATGCGAAAAACACCGTTTACCTGCAGATGAATAG TCTGCGTCCTGAAGATACCGCATTGTATTATTGTGCAAC
[0221] C
[0222] 60 na aCXCR4 FR4 TGGGGTCAGGGAACCCTGGTCACCGTCTCCTCA
[0223] 61 na alCOS CDR1 GGAAGCATCTTCCGTATCAATGTCATGGGC
[0224] 62 na alCOS CDR2 GCTACTGCTACTGGTGGTAGCACAACC
[0225] 63 na alCOS CDR3 GTCGACGGTGGTGGCTTATATGTGATGGACTAC
[0226] 64 na alCOS FR1 GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCA GCCTGGAGGATCTCTTAGACTCTCCTGTGCAGCCTCT
[0227] 65 na alCOS FR2 TGGTACCGCCAGGCTCCAGGGAAGCAGCGCGAGTTGGT CGCG
[0228] 66 na alCOS FR3 TATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGC GACAACGCCAAGAACACGGTGTATCTGCAAATGAACAG CCTGAGACCTGAGGACACGGCCGTCTATTACTGTAATGC
[0229] A
[0230] 67 na alCOS FR4 TGGGGCCAGGGTACGCTGGTCACCGTCTCCTCA
[0231] 68 na aALB CDR1 GGTTTCACCTTTCGTAGCTTCGGTATGAGC
[0232] 69 na aALB CDR2 AGCATCAGCGGTTCTGGCTCTGATACCCTC
[0233] 70 na aALB CDR3 GGTGGTTCCCTGTCTCGC
[0234] 71 na aALB FR1 GAGGTGCAATTGGTGGAGTCTGGGGGAGGTGTTGTTCA GCCGGGTGGCTCCCTGCGTCTGTCTTGCGCAGCTTCT
[0235] 72 na aALB FR2 TGGGTACGTCAGGCTCCAGGCAAAGGCCCGGAGTGGGT CTCT
[0236] 73 na aALB FR3 TACGCGGATTCCGTGAAAGGTCGCTTCACCATTAGCCGT GACAACAGCAAAAACACCCTGTACCTGCAGATGAACTC TCTGCGCCCGGAAGACACTGCCCTGTACTACTGTACGAT
[0237] C
[0238]
[0239] 74 na aALB FR4 TCCTCTCAGGGGACCCTGGTCACCGTCTCCTCA
[0240] Aspects of the invention and particular embodiments thereof
[0241] The invention relates to several aspects as set out above in the summary of the invention. These aspects comprise alternative embodiments and preferred embodiments, which are described below.
[0242] Anti-ICOS*anti-CXCR4 multispecific binding protein
[0243] In a first aspect, the invention provides a multispecific binding protein comprising:(a) a first antigen-binding domain (ABD) specifically binding to an extracellular domain of ICOS; and
[0244] (b) a second ABD specifically binding to an extracellular domain of CXCR4.
[0245] The inventors have found that a multispecific binding protein comprising an anti-ICOS ABD and an anti-CXCR4 ABD is able to inhibit or disrupt interaction between Tfh and B cells, thereby inhibiting Tfh-induced IgG and IgM production by B cells (Example 1). Monospecific binding proteins binding only CXCR4 or ICOS were not able to achieve the same effect, either when administered individually or in combination (Examples 1 and 2). Without wishing to be bound by theory, and considering that both ICOS and CXCR4 follow specific dynamic movements during the formation of Immune Synapses (Felce et al., https: / / doi.org / 10.3389 / fcell.2020.608484 and Demetriou et al., https: / / doi.org / 10.1038 / s41590-020-0770-x) the inventors propose that the effect of the bispecific anti-ICOS *anti-CXCR4 antibody can be explained at least partially via the following mechanism: The anti-CXCR4 binding domain functions by anchoring the bispecific anti-ICOS*anti-CXCR4 antibody to a Tfh cell or B cell. When the anti-ICOS binding domain of the bispecific antibody binds to ICOS expressed on a Tfh cell, this prevents free movement of ICOS, because ICOS is “chained” to CXCR4 on the same Tfh cell (cis mechanism) or on a neighbouring B cell (trans mechanism) via the bispecific antibody. The impaired movement of ICOS has the effect of preventing synapse formation. This is surprising because CXCR4 was previously only known to act by binding to its native ligand, CXCL12.
[0246] The IgG and IgM production by B cells required the presence of Tfh cells, since IgG and IgM could not be detected in the supernatants of not-Tfh-B cells cocultures (Example 3). Moreover, the multispecific aICOS-aALB-aCXCR4 protein was able to inhibit IgG and IgM production with an IC50 in the nanomolar range. Notably, the multispecific alCOS-aALB-aCXCR4 protein was able to inhibit survival of B cells and formation of plasmablasts and plasma cells in a Tfh / B cell co-culture (Example 4). The results of MIMIC Recall assay using Fluzone QIV confirmed the inhibitory effect of aICOS-aALB-aCXCR4 on hemagglutinin (HA) specific B cell responses to Fluzone (Example 5).
[0247] The term "multi specific binding protein" refers herein to a binding protein having at least two different antigen-binding domains (ABD), i.e. a first and a second antigen-binding domain, defined by different amino acid sequences. The multispecific binding protein retains the binding specificity of the first ABD and of the second ABD. In addition, the multispecific binding protein preferably retains the biological activity of the first ABD and of the second ABD, wherein the biological activity of the first or second ABD is selected from agonism or antagonism, or in particular from agonism, inverse agonism, antagonism, and neutral antagonism towards the target.The multispecific binding protein may be a single chain or a multi-chain protein, i.e. comprising two or more polypeptide chains. The multispecific binding protein may be symmetric, i.e. the first and second ABD have the same structure (e.g. both are a VHH), or asymmetric, i.e. the first and second ABD do not have the same structure (e.g. an ABD is a scFv and an ABD is a VHH).
[0248] The term "antigen-binding domain" (ABD) (or simply "binding domain") refers herein to a polypeptide capable of specifically binding to its specific target antigen and comprising the minimal structural requirements derived from an antibody, in particular H-CDR1, H-CDR2, and H-CDR3, which allow for target binding. For example, an antigen-binding domain may be an antibody or a fragment thereof. Indeed, it has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Many formats of antigen binding domains are known in the art (e.g. as described by Brinkmann, U, and Kontermann, RE, 2017. mAbs. 9(2), 182-212) and no particular limitations are intended.
[0249] The first target molecule of the multispecific binding protein described herein is ICOS. The term "ICOS" as used herein refers to the protein encoded by the ICOS gene (NTH Gene ID: 29851), also known as Inducible T Cell Costimulator or CD278 antigen. ICOS is an important regulator of Tfh cells. Activated B cells express ICOS ligand (ICOS-L) which is critical for Tfh cell development and maintenance. ICOS is a type I transmembrane glycoprotein that belongs to the CD28 family of co-stimulatory immunoreceptors. It is present on the T cell surface as a disulfide bond-linked homodimer and it is rapidly upregulated upon TCR cross-linking and / or CD28 co-stimulation. On the other hand, ICOS-L (CD275) belongs to the B7 family and is expressed on the surface of APCs, B cells, and non-hematopoietic cells under inflammatory conditions. Stimulation of the ICOS receptor on T cells by ICOS-L on activated B cells is required for the development of follicular helper T (Tfh) cells.
[0250] ICOS amino acid sequence comprises a signal peptide (residues 1-20 of SEQ ID NO: 2), an extracellular domain (residues 21-140 of SEQ ID NO: 2), a transmembrane domain (residues 141-161 of SEQ ID NO: 2), and cytoplasmic tail (residues 162-199 of SEQ ID NO: 2).
[0251] Herein, the term "ICOS" preferably relates to human ICOS, and, in particular, to a protein comprising the amino acid sequence according to SEQ ID NO: 2 or a variant of said amino acid sequence.
[0252] The second target molecule of the multispecific binding protein described herein is CXCR4.
[0253] The term "CXCR4" as used herein refers to the protein encoded by the CXCR4 gene (NIH Gene ID: 7852), also known as C-X-C motif chemokine receptor 4 or fusin or CD184 antigen. CXCR4, is an alpha-chemokine receptor specific for stromal-derived-factor- 1 (SDF-1), which isalso called CXCL12, a molecule endowed with potent chemotactic activity for lymphocytes. CXCR4 acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Unusually for chemokines, CXCL12 and CXCR4 are a relatively "monogamous" ligand- receptor pair, whereas other chemokines tend to use several different chemokine receptors. The CXCR4 protein has 7 transmembrane a-helices, an N-terminal extracellular domain (aa 1-38 of SEQ ID NO: 1), three extracellular loops ECLl(aa 100-110 of SEQ ID NO: 1), ECL2 (aa 175-195 of SEQ ID NO: 1), ECL3 (aa 262-282 of SEQ ID NO: 1), and an intracellular C-terminal region (aa 303-352 of SEQ ID NO: 1). The N-terminal extracellular domain binds to CXCL12, whereas the intracellular C-terminal domain binds to a G-protein.
[0254] Herein, the term "CXCR4" preferably relates to human CXCR4, and, in particular, to a protein comprising the amino acid sequence according to SEQ ID NO: 1 or a variant of said amino acid sequence.
[0255] Preferably, the multispecific binding protein anti-ICOS*anti-CXCR4 is able to simultaneously bind CXCR4 on a B cell and ICOS on a Tfh cell, thereby blocking interaction of ICOS with ICOS-L on B cells, and synapse formation between the Tfh cell and the B cell. Alternatively, the multispecific binding protein anti -ICOS x anti-CXCR4 is able to simultaneously bind CXCR4 and ICOS on a Tfh cell, thereby preventing interaction of ICOS with ICOS-L on B cells and formation of functional immune synapsis.
[0256] Preferably, the anti-ICOS ABD is a non-antagonist or an antagonist of ICOS, more preferably, the anti-ICOS ABD is an antagonist of ICOS. As used herein, an "antagonist of ICOS" refers to an anti-ICOS ABD that competes with ICOS-L, thereby inhibiting ICOS-L induced ICOS signaling. As used herein, "a non-antagonist of ICOS " means that the ABD binds to ICOS but without preventing or inhibiting the activation of ICOS. For example, "a non-antagonist of ICOS" may be an agonist of ICOS, or an ICOS binder, i.e. an ABD which does not compete with ICOS-L for binding and has no effect on ICOS state. The term "agonist of ICOS" as used herein refers to an anti-ICOS ABD that activates an intracellular response when it binds to the ICOS similarly to the native ICOS ligand ICOS-L.
[0257] Preferably, the second ABD is an antagonist of CXCR4 or a non-antagonist of CXCR4, more preferably the second ABD is an antagonist of CXCR4.
[0258] As used herein, an "antagonist of CXCR4" means that the ABD inhibits CXCR4 signaling by binding to CXCR4 to prevent or inhibit the binding and / or activation of CXCR4 by CXCL12, thereby inhibiting CXCL12-induced CXCR4 signaling. In particular, an antagonist of CXCR4 may be a neutral antagonist. A "neutral antagonist" is defined herein as a CXCR4 ligand thatcompetitively inhibit agonist action without affecting the equilibrium between an active state and an inactive state (Sato et al., 2016. Endocrine Journal, 63 (6), 507-514).
[0259] As used herein, "a non-antagonist of CXCR4" means that the ABD binds to CXCR4 but without preventing or inhibiting the binding and / or activation of CXCR4. For example, "a nonantagonist of CXCR4" may be an agonist of CXCR4, or a CXCR4 binder, i.e. an ABD which does not compete with CXCL12 for binding and has no effect on CXCR4 state.
[0260] As used herein, "active state" of CXCR4 refers to the active conformation of the receptor that is able to activate CXCR4-associated G proteins and intracellular signalling pathways. As used herein, "inactive state" of CXCR4 refers to the inactive conformation of the receptor that is not able to activate CXCR4-associated G proteins and intracellular signalling pathways (Bianchi and Mezzapelle, 2020. Front. Immunol., 11).
[0261] As used herein, an "agonist of CXCR4" refers to a ligand that activates an intracellular response when it binds to the CXCR4 similarly to the native CXCR4 ligand CXCL12.
[0262] As used herein, an "inverse agonist of CXCR4" refers to a ligand that binds to the same site as an agonist but induces a pharmacological response opposite to that of the agonist. An inverse agonist decreases the activity of CXCR4 below the basal level.
[0263] As it will be clear to the skilled person, such activity as an agonist or an antagonist may be determined using any suitable assay known in the art, such as the assays described herein or in the prior art, and usually using in vitro cellular assays. In particular, an activity as an agonist may be such that the measured biological or physiological activity of CXCR4 or ICOS is increased by at least 1%, at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% or more, as compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the agonist. An activity as antagonist may be such that the measured biological or physiological activity of CXCR4 or ICOS in presence of the agonist and antagonist is decreased by at least 1%, at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% or more, as compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the antagonist. An activity as inverse agonist may be such that the measured biological or physiological activity of CXCR4 or ICOS in presence of the inverse agonist is decreased by at least 1%, at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% or more, as compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the inverse agonist.
[0264] Additionally or alternatively, an activity as an agonist may be such that the measured biological or physiological activity of CXCR4 or ICOS is increased by at least 2-fold, 5 -fold, 10-fold, 50-fold, 100-fold 150-fold, 200-fold, 250-fold, 500-fold, 1000-fold, 10,000-fold, etc., as compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the agonist. Additionally or alternatively, an activity as an antagonist may be such that the measured biological or physiological activity of CXCR4 or ICOS in presence of agonist and antagonist is decreased by at least 2-fold, 5 -fold, 10-fold, 50-fold, 100-fold 150-fold, 200-fold, 250-fold, 500-fold, 1000-fold, 10,000-fold, etc., as compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the antagonist. Additionally or alternatively, an activity as an inverse agonist may be such that the measured biological or physiological activity of CXCR4 or ICOS in presence of the inverse agonist is decreased by at least 2-fold, 5 -fold, 10-fold, 50-fold, 100-fold 150-fold, 200-fold, 250-fold, 500-fold, 1000-fold, 10,000-fold, etc., as compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the inverse agonist.
[0265] These assays may be performed using individually the first ABD, the second ABD, or the multispecific protein of the first aspect. A biological or physiological activity to be measured may for example be the binding of aCXCR4 or anti-ICOS to one of its ligands, the competing with a natural ligand, and / or the expression of a protein or gene that is known to be regulated by CXCR4 or ICOS.
[0266] The term "extracellular domain of CXCR4" as used herein relates to the N-terminal extracellular domain and the three extracellular loops ECL1, ECL2, and ECL3 of CXCL4, and in particular to amino acids 1-38, 100-110, 175-195, and 262-282 of SEQ ID NO: 1. Preferably, the second ABD binds to an epitope of the extracellular domain of CXCR4 within amino acids 1-38, 100-110, 175-195, and / or 262-282 of SEQ ID NO: 1, preferably within amino acids 1-38, amino acids 100-110, amino acids 175-195, and / or amino acids 262-282 of SEQ ID NO: 1, or within fragments thereof.
[0267] The term "extracellular domain of ICOS" as used herein relates to amino acids 21-140 of SEQ ID NO: 2. Preferably, the first ABD binds to an epitope of the extracellular domain of ICOS within amino acids 21-140 of SEQ ID NO: 2, or within a fragment thereof.
[0268] Antigen-binding domain (ABD)
[0269] Preferably, in the multispecific binding protein of the first aspect, the first ABD and the second ABD comprise a mAb, heavy chain antibody (HCAb), immunoglobulin single variable domain (ISVD), preferably a VH, VHH, humanized VHHs single domain antibody (sdAb), or diabody (dAb); an IgG, a scFv, scFv?, scFv4, a Fv, Fab, Fab', F(ab')2, double variable domain(DVD), triple variable domain (TVD), or a single chain antibody -like protein scaffold, in particular an anticalin, DARPins, affibody, affimer, avimer, neutrophil gelatinase-associated lipocalin (NGAL) or evasin, more preferably a humanized VHH. Preferably, in the multispecific binding protein of the first aspect, the first ABD comprises a monoclonal antibody (mAb), heavy chain antibody (HCAb), immunoglobulin single variable domain (ISVD), preferably a VH, VHH, humanized VHHs, single domain antibody (sdAb), or diabody (dAb); an IgG, a scFv, scFv?, scFv4, a Fv, Fab, Fab', F(ab')2, double variable domain (DVD), triple variable domain (TVD), or a single chain antibody-like protein scaffold, in particular an anticalin, DARPins, affibody, affimer, avimer, neutrophil gelatinase-associated lipocalin (NGAL) or evasin, more preferably a humanized VHH. Preferably, in the multispecific binding protein of the first aspect, the second ABD comprises a mAb, heavy chain antibody (HCAb), immunoglobulin single variable domain (ISVD), preferably a VH, VHH, humanized VHHs, single domain antibody (sdAb), or diabody (dAb); an IgG, a scFv, scFv?, scFv4, a Fv, Fab, Fab', F(ab')2, double variable domain (DVD), triple variable domain (TVD), or a single chain antibody -like protein scaffold, in particular an anticalin, DARPins, affibody, affimer, avimer, neutrophil gelatinase-associated lipocalin (NGAL) or evasin, more preferably a humanized VHH.
[0270] The term "scFv" (single-chain variable fragment) as used herein refers to an antibody fragment having the general structure:
[0271] VH-linker-VL
[0272] or when referring to the CDRs (complementarity-determining regions) and FRs (framework regions), the general structure:
[0273] HFR1 -HCDR1 -HFR2-HCDR2-HFR3 -HCDR3 -HFR4-linker-LFRl -LCDR1 -LFR2- LCDR2-LFR3 -LCDR3 -LFR4.
[0274] One common flexible linking peptide is (G4S)x or a functional variant thereof, wherein x may be 1, 2, 3, 4, 5, 6, 7 or 8. Preferably, a linker connecting the VH and VL domain of an scFv comprises, preferably consists of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-48. Optionally, the association of the VH and VL can be stabilized by one or more intermolecular disulfide bonds.
[0275] A "bispecific scFv" refers herein to a fusion polypeptide comprising two scFvs from different antibodies or amino acid sequences from four different genes linked by a peptide linker. A "multispecific scFv" refers herein to a fusion polypeptide comprising more than two (e.g. three, four, or more) scFvs from different antibodies, or amino acid sequences from more than four different genes linked by a peptide linker.The term "immunoglobulin single variable domain" (ISVD), interchangeably used with "single variable domain", defines herein immunoglobulin molecules wherein the antigen binding site is present on, and formed by, a single immunoglobulin domain. This distinguishes ISVDs from conventional immunoglobulins, e.g. monoclonal antibodies (mAb) or their fragments such as Fab, Fab’, F(ab’)2, scFv, di-scFv, wherein two immunoglobulin domains, in particular two variable domains, interact to form an antigen binding site.
[0276] An ISVD may be a light chain variable domain sequence (e.g., a VL-sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g., a VH-sequence or VHH sequence) or a suitable fragment thereof; as long as it is capable of forming a single antigen binding unit, i.e., a functional antigen binding unit that essentially consists of the single variable domain, such that the single antigen binding domain does not need to interact with another variable domain to form a functional antigen binding unit. An immunoglobulin single variable domain (ISVD) can for example be a heavy-chain ISVD, such as a VHH, including a humanized VHH, or a VH, such as a human VH, preferably a VHH or a humanized VHH. Heavy chain ISVDs can be derived from a conventional four-chain antibody or from a heavy chain antibody, i.e., of an antibody devoid of light chain (Hamers-Casterman et al., 1993. Nature 363: 446-448).
[0277] The term "single-domain antibody" as used herein refers to a peptide chain of approximately 110 amino acids in length, comprising a variable domain (VH) of a heavy chain antibody or a common immunoglobulin G (IgG).
[0278] The term "VHH" or "VHH domain" refers herein to the antigen binding immunoglobulin variable domain of a heavy chain antibody. The term "VHH" has been chosen in order to distinguish these variable domains from the heavy chain variable domains that are present in conventional 4-chain antibodies, which are normally referred to herein as "VH domains", and from the light chain variable domains that are present in conventional 4-chain antibodies, which are referred to herein as "VL domains". The generation of immunoglobulin sequences, such as VHHs, has been described extensively in various publications, such as Hamers-Casterman et al., 1993 and Muyldermans et al., 2001 (Reviews in Molecular Biotechnology 74: 277-302, 2001).
[0279] Generally, an ISVD or VHH can be defined as an immunoglobulin sequence with the general structure:
[0280] FR1 - CDR1 - FR2 - CDR2 - FR3 - CDR3 - FR4
[0281] in which FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which one or more of the Hallmark residues are preferably as defined in Table 3. For example, one or moreof the amino acid residues at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to the Kabat numbering are chosen from the Hallmark residues as defined in Table 3.
[0282] A "humanized VHH" comprises an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VHH domain, but that has been humanized, i.e. by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring VHH sequence, in particular in the framework sequences, by one or more of the amino acid residues that occur at the corresponding position(s) in a VH domain from a conventional 4-chain antibody from a human being. This can be performed in a manner known per se, which will be clear to the skilled person, for example on the basis of the prior art (e.g. WO 2008 / 020079 Al). Such humanized VHHs can be obtained in any suitable manner known per se and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring VHH domain as a starting material.
[0283] The term "single chain antibody-like protein scaffold" as used in the context of the invention refers to a small single-domain molecule (1-20 kDa) composed of two parts that are analogous to antibodies. Preferably, a single chain antibody-like protein scaffold is selected from the group comprising anticalin, DARPins (designed ankyrin repeat proteins), affibody, affimer, avimer, neutrophil gelatinase-associated lipocalin (NGAL) and evasin. Single chain antibody-like protein scaffolds are known in the state of the art and have been reviewed for example by Luo R., el al., 2022. RSC Chem. Biol., 3, 830-847.
[0284] Antibody sequences
[0285] The boundaries of the complementarity determining regions (CDRs) and of framework regions (FRs) within the variable domains can be determined using any method known in the art or using new methods. It is to be understood that such determination methods only decide which amino acids of the same variable regions are counted towards a certain CDR (or FR) and that they do not define truly new or different CDR or FR regions. For example, the CDRs and / or FRs boundaries may be determined according to AbM, IMGT, Kabat or Chothia, preferably according to AbM.
[0286] The AbM numbering has been described by Kontermann and Diibel (Eds. 2010, Antibody Engineering, vol 2, Springer Verlag Heidelberg Berlin, Martin, Chapter 3, pp. 33-51). According to this method, FR1 of an ISVD comprises the amino acid residues at positions 1-25, CDR1 of an ISVD comprises the amino acid residues at positions 26-35, FR2 of an ISVD comprises the amino acids at positions 36-49, CDR2 of an ISVD comprises the amino acid residues at positions 50-58,FR3 of an ISVD comprises the amino acid residues at positions 59-94, CDR3 of an ISVD comprises the amino acid residues at positions 95-102, and FR4 of an ISVD comprises the amino acid residues at positions 103-113.
[0287] Preferably, the boundaries of the CDRs of the anti-ICOS ABD are determined according to AbM, wherein CDR1, CDR2 and CDR3 of the anti-ICOS heavy chain variable domain according to SEQ ID NO: 4 comprise the sequences of SEQ ID NOs: 20, 21 and 22, respectively.
[0288] Preferably, the boundaries of the CDRs of the anti-CXCR4 ABD are determined according to AbM, wherein CDR1, CDR2 and CDR3 of the anti-CXCR4 heavy chain variable domain according to SEQ ID NO: 3 comprise the sequences of SEQ ID NOs: 13, 14 and 15, respectively.
[0289] Alternative CDR boundaries (Kabat, Chothia, or IMGT) and thereby sequences are given in Table 2.
[0290] Generally, it is preferred that each ABD comprises at least two framework regions (FRs) FR2 and FR3 within a structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 of which FR1 and / or FR4 may be absent. In a preferred embodiment, FR1 and FR4 are present.
[0291] Preferably, in the anti-ICOS ABD, the FRs are heavy chain framework regions HFR1, HFR2, HFR3 and HFR4 of the heavy chain variable domain according to SEQ ID NO: 4, or are HFR variants thereof having at least 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to said HFR1, HFR2, HFR3 and HFR4, respectively.
[0292] Preferably, in the anti-CXCR4 ABD, the FRs are heavy chain framework regions HFR1, HFR2, HFR3 and HFR4 of the heavy chain variable domain according to SEQ ID NO: 3, or are HFR variants thereof having at least 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to said HFR1, HFR2, HFR3 and HFR4, respectively.
[0293] FR boundaries (IMGT, Kabat or Chothia) and thereby sequences are given in Table 2. Thus, in the multispecific binding protein of the first aspect, the first ABD preferably comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 4, and more preferably CDR1 according to SEQ ID NO: 20, CDR2 according to SEQ ID NO: 21, and CDR3 according to SEQ ID NO: 22. Additionally or alternatively, in the multispecific binding protein of the first aspect, the second ABD comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3, and more preferably CDR1 according to SEQ ID NO: 13, CDR2 according to SEQ ID NO: 14, and CDR3 according to SEQ ID NO: 15.
[0294] In one embodiment of the multispecific binding protein of the first aspect:
[0295] (a) the first ABD comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 4;
[0296] and(b) the second ABD comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3.
[0297] In a preferred embodiment of the multispecific binding protein of the first aspect:
[0298] (a) the first ABD comprises CDR1 according to SEQ ID NO: 20, CDR2 according to SEQ ID NO: 21, and CDR3 according to SEQ ID NO:22; and
[0299] (b) the second ABD comprises CDR1 according to SEQ ID NO: 13, CDR2 according to SEQ ID NO: 14, and CDR3 according to SEQ ID NO: 15.
[0300] Preferably, in the multispecific binding protein of the first aspect, the first and the second ABD comprise a VHH, the first ABD comprises a VHH, or the second ABD comprises a VHH, preferably a humanized VHH.
[0301] In the multispecific binding protein of the first aspect, the first ABD preferably comprises a VHH sequence having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 4. Moreover, in the multispecific binding protein of the first aspect, the second ABD preferably comprises a VHH sequence having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 3. More preferably, in the multispecific binding protein of the first aspect, the first ABD comprises a VHH sequence having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 4, and the second ABD comprises a VHH sequence having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 3.
[0302] Suitable anti-ICOS and anti-CXCR4 antibodies to obtain the first and second ABD to manufacture a multispecific binding protein according to the first aspect are known in the prior art. For example, the anti-CXCR4 ABD of the multi specific binding protein of the first aspect may comprise a VHH, in particular a humanized VHH, having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 238-253 disclosed in the international patent application WO 2009 / 138519 Al.
[0303] In a particular embodiment, the multispecific binding protein according to the first aspect comprises an amino acid sequence having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 9, i.e. a multispecific binding protein including a first ABD comprising an anti-ICOS VHH, a second ABD comprising an anti-CXCR4 VHH, and wherein the first ABD and the second ABD are covalently indirectly linked by a peptide linker comprising an anti-albumin (anti-ALB) VHH and a peptide linker connecting the anti-ICOS ABD and the anti-ALB VHH, and a peptide linker connecting the anti-ALB VHH and the anti-CXCR4 ABD, and wherein the anti-ICOS ABD is located C-terminally of the anti-ALB and of the anti-CXCR4 ABD.Half-life increasing moiety
[0304] An embodiment of the invention provides a multispecific binding protein according to the first aspect, wherein the binding protein further comprises a half-life increasing moiety.
[0305] The term "half-life" relates herein to the period of time which is needed to eliminate half of the activity, amount, or number of multispecific binding proteins. Therefore, the half-life of a multispecific binding protein is indicative for the stability of said multispecific binding protein. The half-life of the multi specific binding protein may influence its effect, and it can be expected that a multispecific binding protein having an increased half-life will be present in human circulation for an increased time period.
[0306] The term "half-life increasing moiety" refers herein to a moiety that is able to increase the half-life (e.g. at least 1.5 times, at least 2 times, at least 5 times, at least 10 times or more than 10 times) of the multispecific binding protein in a mammal, such as a human subject, after administration compared to a multispecific binding protein with the same structure except for lacking the half-life increasing moiety. Thus, the term half-life preferably refers herein to an “z z vivo half-life”.
[0307] Generally, the multispecific binding protein of the invention comprising a half-life increasing moiety has a half-life that is preferably at least 1.5 times, at least 2 times, at least 5 times, at least 10 times or more than 10 times, greater than the half-life of the corresponding multispecific binding protein without said half-life increasing moiety.
[0308] The in vivo half-life of the multispecific binding protein of the first aspect can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art, and may for example generally involve the steps of suitably administering to a human or another mammal a suitable dose of the multispecific binding proteins; collecting blood samples or other liquid samples from said animal; determining the level or concentration of the multi specific binding proteins in said sample; and calculating from the data thus obtained, the time until the level or concentration of the multispecific binding proteins of the invention has been reduced by 50% compared to the initial level upon dosing. The half-life is preferably expressed as terminal half-life (tl / 2-beta). Thus, as used herein, an increase in half-life in particular refers to an increase in the tl / 2-beta. Methods for pharmacokinetic analysis and determination of half-life are known in the prior art, e.g. in Kenneth, A et aL, Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and in Peters et al., Pharmacokinetic analysis: A Practical Approach (1996).The type of half-life increasing moiety is not generally restricted and may for example be selected from the group consisting of a polyethylene glycol (PEG), an antibody Fc portion, and an ABD with binding specificity to a serum protein, preferably human serum albumin (ALB).
[0309] More preferably, the half-life increasing moiety is an ABD with binding specificity to a serum protein, preferably human serum albumin (ALB) or serum immunoglobulin. For example, the ABD may comprise an ISVD, in particular a VH, VHH, humanized VHHs, with binding specificity to a serum protein, preferably human serum albumin or a serum immunoglobulin, such as a serum IgG. In one embodiment, the half-life increasing moiety is a VHH binding to serum albumin (anti -ALB or aALB).
[0310] For example, the ABD with binding specificity to serum albumin may be selected from the albumin binding protein described in WO 2012 / 175741, WO2015 / 173325, W02017 / 080850, WO2017 / 085172, WO2018 / 104444, WO2018 / 134235, and WO2018 / 134234. In addition, a VHH binding to serum albumin may be selected from Alb-1, Alb-3, Alb-4, Alb-5, Alb-6, Alb-7, Alb-8, Alb-9, Alb-10 (WO 2006 / 122787 Al) and Alb-23 (WO 2012 / 175400 Al) or a variant thereof.
[0311] In a preferred embodiment, the half-life increasing moiety is a VHH binding to serum albumin according to SEQ ID NO: 5 (also referred to as anti-ALB or aALB). Preferably, the boundaries of the CDRs of the anti-ALB ABD are determined according to AbM, wherein CDR1, CDR2 and CDR3 of the anti-ALB heavy chain variable domain according to SEQ ID NO: 5 comprise the sequences of SEQ ID NOs 27, 28 and 29, respectively. Thus, in the multispecific binding protein of the first aspect, the anti-ALB ABD preferably comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 5, and more preferably CDR1 according to SEQ ID NO: 27, CDR2 according to SEQ ID NO: 28, and CDR3 according to SEQ ID NO: 29. Alternative CDR boundaries (Kabat, Chothia, or IMGT) and thereby sequences are given in Table 2.
[0312] Linkage between the first and second ABD
[0313] An embodiment of the first aspect provides a multispecific binding protein, wherein the first ABD and the second ABD are covalently linked directly or indirectly by a linker.
[0314] The term "covalently linked directly" refers herein to a direct covalent linkage between the first and second ABD so that for example the C-terminus or N-terminus of the first ABD is covalently directly linked to the N-terminus or C-terminus of the second ABD or of the half-life increasing moiety (‘HLM’) , and / or the N-terminus or C-terminus of the second ABD is covalently directly linked to the N-terminus or C-terminus of the half-life increasing moiety.The term "covalently linked indirectly by a linker" means that the first ABD and the second ABD are linked by a peptide linker, preferably the linker comprises a half-life increasing moiety, so that the first ABD is linked directly or by a peptide linker to the half-life increasing moiety and the half-life increasing moiety is linked directly or by a peptide linker to the second ABD. Accordingly, the linker between the first and second ABD optionally comprises a half-life increasing moiety and one or more peptide linkers. Therein, the following layouts are possible: the N-terminus or C-terminus of the first ABD is linked directly or by a peptide linker to the N-terminus or C-terminus of the half-life increasing moiety, and the N-terminus or C-terminus of the half-life increasing moiety is linked directly or by a peptide linker to the N-terminus or C-terminus of the second ABD. Additionally or alternatively, the first ABD and the second ABD are linked by a peptide linker by their C-termini or N-termini, preferably by the C-termini.
[0315] Therefore, in the multispecific binding protein of the first aspect, the first ABD may be located C-terminally or N-terminally of the second ABD, preferably C-terminally.
[0316] Types of covalent bonds include, but are not limited to, peptide bonds, isopeptide bonds, disulphide bonds, and thioether bonds.
[0317] The term "linker" refers herein to any means that serves to join two distinct functional units (e.g. domains or regions on a polypeptide chain). Types of linkers include, but are not limited to, chemical linkers, peptide and polypeptide linkers. The sequences of the peptide and polypeptide linkers are not limited. Peptide linkers are preferably non-immunogenic and flexible, such as those comprising serine and glycine sequences. Depending on the particular construct, the linkers may be long (i.e. 10 amino acids or more) or short (i.e. 9 amino acids or less). Exemplary linkers are short alanine linkers, glycine-serine-rich linkers, and linkers derived from various immunoglobulin and non-immunoglobulin molecule. A linker can be designed by using online tools, such as the web-based program run by the Centre for Integrative Bioinformatics VU (IBIVU) at Vrije University of Amsterdam (http: / / www.ibi.vu.nl / programs / linkerdbwww / ), or the program LINKER (Xue F, Gu Z, Feng JA. 2004. LINKER: a web server to generate peptide sequences with extended conformation. Nucleic Acids Res. 32:W562-5). For example, a linker linking two ABDs or an ABD and a HLM of the multispecific binding protein can be selected from the group consisting of SEQ ID NOs: 34-48.
[0318] The inventors have found that an anti-ICOS*anti-CXCR4 bispecific protein generated by genetic fusion (aICOS-aALB-aCXCR4) has similar activity to a bispecific protein generated by bioconjugation (aICOS-SpyTag / aCXCR4-SpyCatcher) (Example 5, Figure 5). Accordingly, a multispecific or bispecific binding protein according to the first aspect may be generated by geneticfusion, chemical conjugation, enzymatic conjugation, or hybrid-hybridoma technology, or a combination thereof. For example, the latter technology involves generating a multispecific or bispecific binding protein with defined specificities by fusing two antibody-producing cells, e.g., hybridomas, to obtain a hybrid-hybridoma cell line that produces for example two different heavy and two different light chains within the same cell, which results in bispecific IgG molecules, as described by Moldenhauer, G., 2011. Bispecific Antibodies from Hybrid Hybridoma. In: Kontermann, R. (eds) Bispecific Antibodies. Springer, Berlin, Heidelberg.
[0319] A multispecific or bispecific binding protein obtained by genetic fusion is a type of fusion protein. The term "fusion protein" refers herein to a protein obtained by genetically fusing the nucleic acids encoding for the first and the second ABD, and optionally one or more peptide linkers connecting the first and second ABD, or genetically fusing the nucleic acids encoding for the first ABD, the second ABD and the half-life increasing moiety and optionally one or more peptide linkers connecting the first ABD and the half-life increasing moiety and / or the half-life increasing moiety and the second ABD. Methods for preparing such fusion proteins are well known in the art, as described for example by WO 1991 / 004329 Al. Suitable fusion protein linkers have been described by Chen, X, et al., 203. Adv Drug Deliv Rev . 65(10): 1357-1369. One embodiment of the present invention provides a multispecific binding protein according to the first aspect, wherein the multispecific binding protein is a fusion protein. In this embodiment, the multispecific binding protein preferably comprises an amino acid sequence having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 9.
[0320] A multispecific binding protein of the first aspect generated by genetic fusion may have one of the following structures in N-terminus to C-terminus direction:
[0321] A) alCOS - aCXCR4;
[0322] B) alCOS - HLM - aCXCR4;
[0323] C) alCOS - aCXCR4 - HLM
[0324] D) aCXCR4 - alCOS;
[0325] E) aCXCR4 - HLM - alCOS
[0326] F) aCXCR4 - alCOS - HLM
[0327] wherein:
[0328] means genetic fusion,
[0329] "alCOS" means an anti-ICOS ABD,
[0330] "aCXCR4" means an anti-CXCR4 ABD.
[0331] The structures of A), B) and C) refer to a multispecific binding protein wherein the first anti-ICOS (alCOS) ABD is located C-terminally of the second anti-CXCR4 (aCXCR4) ABD. Thestructures of D), E) and F) refer to a multispecific binding protein wherein the first anti-ICOS ABD is located N-terminally of the second anti-CXCR4 ABD.
[0332] A further embodiment of the present invention provides a multispecific binding protein according to the first aspect, wherein the multispecific binding protein is a conjugate. For example, two ABDs in the multispecific binding protein of the first aspect (e.g. the first and second ABD, or the first ABD and the half-life increasing moiety, or the half-life increasing moiety and the second ABD) may be chemically or enzymatically conjugated. Methods for chemical conjugation of two antigen binding domains are well known in the prior art, and include but are not limited to using hetero-bifunctional chemical crosslinkers (e.g. succinimidyl 3-(2-pyridyldithio)propionate (SPDP) / dithiothreitol (DTT), or Traut’s reagent / succinimidyl 4-(N-maleimidomethyl)cyclohexane-l -carboxylate (SMCC)), homo-bifunctional chemical crosslinkers (e.g. DTNB or o-phenylenedimaleimide (PDM)), the SpyCatcher / SpyTag system (B. Zakeri etal., 2012. Proc Natl Acad Sci U.S.A. 109 (12) E690-E697), the SpyCatcher / SpyLock / SpyTag system, or split inteins (Hofmann T, etal., 2020. IntJMol Sci. 21(18):6551). Enzymatic conjugation refers for example to the use of a transglutaminases (TGase) and compatible peptidyl linkers or of a Sortase A (SrtA). Methods for chemical or enzymatic conjugation have been described in the prior art, for example in Szijj, P., Chudasama, V., 2021. Nat Rev Chem 5, 78-92. In this embodiment, an ABD may bind the other ABD of the multispecific binding protein by its C-terminus, N-terminus, or amino acidic side chain, preferably both the first ABD and the second ABD are linked by their C-termini or N-termini, more preferably by their C-termini. For example, a conjugate multispecific protein according to the first aspect is generally indicated as aICOS / aCXCR4, aICOS / HLM / aCXCR4, aICOS / aCXCR4 / HLM, aICOS-HLM / aCXCR4, and aICOS / aCXCR4-HLM, wherein “ / ” means that the two ABDs or ABD and HLM are conjugated. In the case of Spy Tag / Spy Catcher conjugation, a multispecific protein according to the first aspect is indicated as aICOS-SpyTag / aCXCR4-SpyCatcher or aICOS-SpyCatcher / aCXCR4-SpyTag, when the ABDs are linked by their C-termini, and as SpyTag-aICOS / SpyCatcher-aCXCR4 or SpyCatcher-aICOS / SpyTag-aCXCR4, when the ABDs are linked by their N-termini.
[0333] A multispecific binding protein according to the first aspect can be of any format. The multi specific binding protein can bind each CXCR4 and / or ICOS with one or more binding domains, for example monovalently, bivalently, trivalently, tetravalently and even with valency of higher order, i.e. the first ABD comprises one, two, three, four or more anti-ICOS ABDs, and / or the second ABD comprises one, two, three, four or more anti-CXCR4 ABDs.In a preferred embodiment, the multispecific binding protein of the first aspect is a “bispecific binding protein” that has specificity for the two target molecules CXCR4 and ICOS, and optionally comprises an additional ABD as half-life increasing moiety.
[0334] A multispecific binding protein according to the first aspect can be a bispecific protein such as a bispecific IgG, BiTE, bi-VHH, charge pair bispecific antibody (CPBA), CovX-Body, DT-IgG, diabody, diabody-Fc, diabody-IgG, diabody-CH3, diabody(KIH), DNLfdock and lock]-Fab3, DNL-Fab2-scFv, dsFv-dsFv’, Fab-arm exchange, F(ab' )2, Fab-Fc(KIH)-scFv, Fab-Fv, Fab-dsFv, Fab-IgG(CR3), Fab-hinge-IgG(CR3), F(ab' )2-scFv, Fab-scFv-Fc [optionally with KIH], Fab-scFv, Fab-scFab-IgG(KIH), Fab-scFv2, Fab-VHH, Fcab, FIT-Ig, IgG2, IgG-crossFab, IgG-dAb, IgG(KIH), IgG(KIH) common LC, IgG-orthogonal Fab, IgG-2scFv, IgG(H)-scFv [two scFvs from the same parental antibody are linked to the C terminus of IgGHC], IgG(L)-scFv, IgG-scFv(LC), IgG(L,H)-Fv, IgG(H)-V, IgG(L)-V [a Fv domain linked to each of the C terminus of the IgG LC], IgG-taFv, LUZ-Y, KA-body, KIH IgG-scFab, mAb2, mAb-dAb, miniantibody, minibody, orthogonal Fab-Fab, orthogonal Fab-IgG(KIH), scDiabody, scDiabody-CH3, scDiabody-Fc, scFab-IgG(KIH), scFv2-albumin, scDb-albumin, 2scFv-IgG, scFv-KIH, scFv2-Fc, scFv2-Fcab, scFv4-Ig, scFv-HSA-scFv, scFv-CH3 [optionally with KIH], scFv2-CHl-CL, scFv-Fc with KIH, CH3 charge pair, EW-RVT, or HA-TF; scFv-(H)IgG [same like IgG(H)-scFv, except that the scFvs are linked to the HC N terminus], scFv-(L)IgG, SEEDbody, taFv-albumin, tandAb, tandem Fab-IgG, tandem scFv, tandem scFv-Fc, taFv-Fc, scFv(KIH)-Fc, tetraval ent HCab [heavychain only Ab], tetravalent Ig, triplebody, TriBi minibody, TriFabs, triple heads, triple dAb / VHH, tetravalent dAb / VHH Two-in-One IgG, VHH-CH1-CL, V(H)-IgG, or V(L)-IgG, which have been described by Brinkmann and Kontermann 2017. The multispecific binding protein may comprise a homodimerization module selected from the group consisting of a hinge-Fc, Fc, CH3 / CH4, and EHD2 or a heterodimerization module selected from the group consisting of a modified hinge Fc, modified Fc, modified CH3, Chl / CL, Ca / Cp, DNL, and a peptide.
[0335] The multispecific binding protein described herein is preferably isolated. An "isolated multispecific binding protein" as used herein refers to a multispecific binding protein which is substantially free of other antigen binding proteins having different antigenic specificities (e.g., an isolated antigen binding protein that specifically binds to CXCR4 and ICOS is substantially free of other antigen binding proteins that specifically bind other antigens than the anti ICOS* ALB *CXCR4 antibody). An isolated multispecific binding protein that specifically binds to CXCR4 and ICOS may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., homologs of the target). In addition, an isolated bispecifc or multispecificantigen binding protein that binds to CXCR4 and ICOS may comprise additional antigen binding sites or domain that bind to other targets, such as serum albumin. Moreover, an isolated antigen binding protein may be substantially free of other cellular material and / or chemicals.
[0336] Nucleic acids
[0337] In a second aspect, the present invention relates to a nucleic acid or nucleic acids encoding the multispecific binding protein of the first aspect.
[0338] The nucleic acid or nucleic acids can be isolated. This can mean that the nucleic acid(s) was / were (i) amplified in vitro, for example by polymerase chain reaction (PCR), (ii) recombinantly produced by cloning, (iii) purified, for example by cleavage and gel-electrophoretic fractionation, or (iv) synthesized, for example by chemical synthesis. In preferred embodiments, a nucleic acid is operably linked to an expression control sequence.
[0339] The nucleic acid or nucleic acids can be prepared by following a method known in the prior art, and / or can be isolated from a suitable natural source. Methods for generating nucleic acids for instance include, but are not limited to, automated DNA synthesis; site-directed mutagenesis; combining two or more naturally occurring and / or synthetic sequences (or two or more parts thereof), introduction of mutations that lead to the expression of a truncated expression product; introduction of one or more restriction sites (e.g. to create cassettes and / or regions that may easily be digested and / or ligated using suitable restriction enzymes), and / or the introduction of mutations by means of a PCR reaction using one or more mismatched primers.
[0340] In some embodiments, the second aspect of the invention relates to a single nucleic acid encoding for a multispecific binding protein according to the first aspect, wherein the multispecific binding protein is a fusion protein, and wherein the nucleic acid has a structure selected from I)-XII) below:
[0341] I) alCOS - aCXCR4;
[0342] II) alCOS - HLM - aCXCR4;
[0343] III) alCOS - aCXCR4 - HLM
[0344] IV) aCXCR4 - alCOS;
[0345] V) aCXCR4 - HLM - alCOS;
[0346] VI) aCXCR4 - alCOS - HLM;
[0347] wherein:
[0348] means genetic fusion,
[0349] "alCOS" means a nucleic acid encoding for an anti-ICOS ABD,"aCXCR4" means the nucleic acid encoding for an anti-CXCR4 ABD,
[0350] "HLM" means a nucleic acid encoding for a half-life increasing moiety.
[0351] The nucleic acids according to I-III encode for a multispecific binding protein wherein the first anti-ICOS ABD is located C-terminally of the second anti-CXCR4 ABD. The nucleic acids according to IV-VI encode for a multispecific binding protein wherein the first anti-ICOS ABD is located N-terminally of the second anti-CXCR4 ABD.
[0352] In alternative embodiments, the second aspect of the invention relates to a set of two nucleic acid molecules together encoding for a multispecific binding protein according to the first aspect, wherein the multispecific binding protein is a conjugate, and wherein each nucleic acid has a structure selected from XIII)-XXIII) below:
[0353] VII) alCOS;
[0354] VIII) aCXCR4;
[0355] IX) alCOS - HLM;
[0356] X) aCXCR4 - HLM;
[0357] wherein "alCOS", "aCXCR4", "L", and "HLM" have the meanings defined above. In other words, the nucleic acids of the second aspect encoding for a multispecific binding protein according to the first aspect of the invention comprise two nucleic acids preferably selected from the group consisting of alCOS, aCXCR4, alCOS - HLM, and aCXCR4 - HLM, Preferably, a nucleic acid or nucleic acids encoding the multispecific binding protein according to the first aspect of the invention is selected from the group consisting of SEQ ID NOs: 44, 45, 46, 47 and 50.
[0358] Vectors
[0359] In a third aspect, the present invention relates to a vector comprising the nucleic acid or nucleic acids of the second aspect.
[0360] Preferably, the vector of the third aspect comprises at least one nucleic acid of the second aspect that is optionally operably linked to one or more expression control sequences, such as promoters, ribosome binding sites, and / or enhancers.
[0361] The term “operably linked” as used herein means that the nucleic acid of the second aspect and the expression control sequence are in a functional relationship with each other. For example, a promoter is “operably linked” to nucleic acid of the second aspect if said promoter is able to initiate or otherwise control / regulate the transcription and / or the expression of the nucleic acid, so that said nucleic acid is considered “under the control of’ said promotor). Generally, when anucleotide sequence and an expression control sequence are operably linked, they are included in the vector in the same direction and usually also in the same reading frame. They will usually also be essentially contiguous (i.e. directly linked), although this may also not be required.
[0362] The nucleic acids of the second aspect encoding the first and the second ABD of the multispecific binding protein may be comprised in the same vector or in separate vectors.
[0363] Cell
[0364] In a fourth aspect, the present invention relates to a cell comprising the nucleic acid or nucleic acids of the second aspect or the vector of the third aspect.
[0365] The cell may be isolated. Preferably, the cell is transfected with the nucleic acid or nucleic acids of the second aspect, more preferably wherein the nucleic acid or nucleic acids is / are comprised in a vector according to the third aspect, or the cell is a progeny cell of the transfected cell. The transfection may be transient or stable, i.e. the nucleic acid or nucleic acids is / are not integrated or is / are integrated into the cell’s genome (stable being preferred). The cell can be a prokaryotic cell (such as Escherichia coli or Pichia pastoris) but preferably is a eukaryotic cell, more preferably a mammalian cell. In one embodiment, the mammalian host cell is a CHO (Chinese hamster ovary) cell or a derivate thereof (such as CH0-K1 and CHO pro-3). In another embodiment, the mammalian host cell is selected from mouse myeloma cells, such as NSO and Sp2 / 0, HEK293 (human embryonic kidney) cells or derivates thereof, such as HEK293T, HEK293T / 17 and / or HEK293F, COS and Vero cells (both green African monkey kidney), and / or HeLa (human cervical cancer) cells.
[0366] A related aspect of the invention is a method for producing the multispecific binding protein of the first aspect, comprising a step of culturing the cell of the fourth aspect, wherein the cell expresses the first and second ABD and optionally a half-life increasing moiety, or a multispecific binding protein, and a step of harvesting the expressed proteins.
[0367] The cell according to the fourth aspect may be a (non-human) host cell capable of expressing the first ABD, second ABD and / or half-life increasing moiety of the multispecific binding protein, or the multispecific binding protein as fusion protein, or comprising the nucleic acid(s) according to the second aspect, and / or the vector comprising the nucleic acid molecule according to the second aspect.
[0368] Pharmaceutical compositionsIn a fifth aspect, the present invention relates to a pharmaceutical composition comprising the multi specific binding protein of the first aspect, the nucleic acid or nucleic acids of the second aspect, the vector of the third aspect, or the cell of the fourth aspect, and at least one pharmaceutically acceptable carrier, diluent, excipient and / or adjuvant.
[0369] A pharmaceutical composition according to the fifth aspect is preferably sterile and contains an effective amount of the multispecific binding protein of the first aspect, the nucleic acid or nucleic acids of the second aspect, the vector of the third aspect, or the cell of the fourth aspect, and at least one pharmaceutically acceptable carrier, diluent, excipient and / or adjuvant.
[0370] The term "pharmaceutically acceptable" refers to the non-toxicity of a material which does not interact with the action of the active component of the pharmaceutical composition.
[0371] The term "carrier" refers herein to an organic or inorganic component, of a natural or synthetic nature, in which the active component (i.e. the multispecific binding protein of the first aspect, the nucleic acid or nucleic acids of the second aspect, the vector of the third aspect, or the cell of the fourth aspect) is combined in order to facilitate, enhance or enable application. Herein, the term "carrier" also includes one or more compatible solid or liquid fillers, diluents or encapsulating substances, which are suitable for administration to a patient. Possible carrier substances for parenteral administration are e.g. sterile water, Ringer, Ringer lactate, sterile sodium chloride solutions, polyalkylene glycols, hydrogenated naphthalenes and, in particular, biocompatible lactide polymers, lactide / glycolide copolymers or polyoxy ethylene / polyoxypropylene copolymers.
[0372] The term "excipient" as used herein is intended to indicate all substances which may be present in a pharmaceutical composition and which are not the active component, such as, e.g., stabilizer, binders, lubricants, thickeners, surface active agents, preservatives, emulsifiers, buffers, flavoring agents, or colorants. The term "stabilizer" as used herein is intended to indicate a substance which may be present in a pharmaceutical composition to improve the stability and efficacy of the active component, e.g. by protecting it from degradation, improving bioavailability, and controlling the release over time. Possible stabilizer substances are e.g. polymers, cyclodextrins, and chelating agents.
[0373] Pharmaceutical compositions are usually provided in a uniform dosage form and may be prepared in a manner known per se. A pharmaceutical composition may e.g. be in the form of a solution or suspension.
[0374] A pharmaceutical composition may further comprise salts, buffer substances, or preservatives, in a pharmaceutically acceptable form. Salts which are not pharmaceutically acceptable may be used for preparing pharmaceutically acceptable salts and are contemplatedherein. Pharmaceutically acceptable salts of this kind comprise in a non-limiting way those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic acids, and the like. Pharmaceutically acceptable salts may also be prepared as alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts or calcium salts. Suitable buffer substances for use in a pharmaceutical composition include acetic acid in a salt, citric acid in a salt, boric acid in a salt and phosphoric acid in a salt. Suitable preservatives for use in a pharmaceutical composition include benzalkonium chloride, chlorobutanol, paraben and thimerosal.
[0375] The pharmaceutical composition of the invention can be administered locally or systemically, preferably systemically. The term "systemic administration" refers herein to the administration of an agent such that the agent is widely distributed in significant amounts throughout the body of an individual and develops a desired effect. For example, the agent may develop its desired effect in the blood and / or reach its desired site of action via the vascular system. Typical systemic routes of administration include administration by direct introduction of the drug into the vascular system, or oral, pulmonary, or intramuscular administration in which the drug is adsorbed, enters the vascular system, and is carried by the blood to the desired site(s) of action. Systemic administration by parenteral route is a particularly preferred route. The term "parenteral administration" refers herein to the administration of an agent such that the agent does not pass through the intestine. The term "parenteral administration" includes, but is not limited to, intravenous administration, subcutaneous administration, intradermal administration, or intraarterial administration. Administration may also be carried out, for example, orally, intraperitoneally or intramuscularly. Pharmaceutical compositions suitable for parenteral administration usually comprise a sterile aqueous or nonaqueous preparation of the active compound, which is preferably isotonic to the blood of the recipient. Examples of compatible carriers and solvents are Ringer solution and isotonic, slightly hypertonic or slightly hypotonic sodium chloride solutions. In addition, usually sterile, fixed oils can be used as solution or suspension medium.
[0376] The pharmaceutical compositions described herein are preferably administered in effective amounts. An "effective amount" refers herein to the amount which achieves a desired reaction or a desired effect alone or together with further doses. In the case of treatment of a particular disease or of a particular condition, the desired reaction preferably relates to inhibition of the course of the disease. This comprises slowing down the progress of the disease and, in particular, interrupting or reversing the progress of the disease. The desired reaction in a treatment of a disease or of a condition may also be delay of the onset or a prevention of the onset of said disease or saidcondition. An effective amount of a pharmaceutical composition described herein will depend on the condition to be treated, the severeness of the disease, the individual parameters of the patient, including age, physiological condition, size and weight, the duration of treatment, the type of an accompanying therapy (if present), the specific route of administration and similar factors. Accordingly, the doses administered of the multispecific binding proteins, nucleic acids, cells or compositions described herein may depend on various of such parameters. In case a reaction in a patient is insufficient with an initial dose, higher doses (or effectively higher doses achieved by a different, more localized route of administration) may be used.
[0377] The pharmaceutical composition of the invention may be administered together with one or more adjuvants. The term "adjuvant" relates to a compound which prolongs or enhances or accelerates an immune response. Various mechanisms are possible in this respect, depending on the various types of adjuvants. Particularly preferred adjuvants are cytokines, such as monokines, lymphokines, interleukins or chemokines, e.g. IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IFNa, IFNy, GM-CSF, LT-a, or growth factors, e.g. hGH. Further known adjuvants are aluminium hydroxide, Freund's adjuvant or oil such as Montanide®, most preferred Montanide® ISA51. Lipopeptides, such as Pam3Cys, are also suitable for use as adjuvants in the pharmaceutical composition of the present invention.
[0378] Medical uses
[0379] In a sixth aspect, the present invention relates to a multispecific binding protein according to the first aspect, a nucleic acid or nucleic acids according to the second aspect, a vector according to the third aspect, a cell according to the fourth aspect, or a pharmaceutical composition according to the fifth aspect for use in medicine.
[0380] The term "use in medicine" as used in the context of the invention refers to the use in the prevention and / or treatment of a disease in a subject.
[0381] In a seventh aspect, the present invention relates to a multispecific binding protein according to the first aspect, a nucleic acid or nucleic acids according to the second aspect, a vector according to the third aspect, a cell according to the fourth aspect, or a pharmaceutical composition according to the fifth aspect for use in a method of treating and / or preventing an immune disease, preferably an auto-immune disease in a subject. The immune disease or an autoimmune disease is, for example, a Tfh / B cell-mediated immune or auto-immune disease, a Tfh cell-mediated immune or auto-immune disease, or a B cell-mediated immune or auto-immunedisease. The autoimmune disease is, for example, an autoimmune disease characterized by the presence of autoreactive or hyperactive B cells.
[0382] The term “immune disease” refers herein to a disease associated to a weak immune disease (e.g. immune deficiency), to an immune system that is too active (e.g. allergy), or that is against healthy tissues or cells of the same subject (e.g. auto-immune disease).
[0383] The term “B cells” refers herein as used in the context of the invention refers to a subgroup of lymphocytes that produce antibody molecules which may be either secreted or inserted into the plasma membrane where they serve as a part of B cell receptors. B cells are usually identified as CD 19+ or CD20+ cells, or CD19+CD20+ cell.
[0384] The term "autoreactive B cell" refers herein to a B cell that is activated by a normal component of a person, i.e. an autoantigen, to produce auto-antibodies.
[0385] The term "hyperactive B cell" refers herein to a B cell that is able to differentiate in a plasma cell producing an abnormal amount of antibodies, and / or autoantibodies. Moreover, a hyperactive B cell shows increased levels of survival and differentiation factors, such as BAFF and interleukin-21. B cell hyperactivation is oft associated with polyclonal hypergammaglobulinaemia (i.e. overproduction of more than one class of immunoglobulins by plasma cells), and presence of autoantibodies such as antinuclear antibodies (ANA) and rheumatoid factor (RF).
[0386] The term "plasmablast" refers herein to a cell derived from an antigen-presenting B cell that proliferated. An "antigen-presenting B cell" is a B cell that encountered and internalized an antigen via a receptor-mediated endocytosis. Plasmablasts are stem cells capable of dividing to yield more cells that may differentiate later into plasma cells. Plasmablasts are capable of secreting antibodies, and may also act as antigen-presenting cells when they internalize antigens. In terms of phenotype, a plasmablast refers herein to a cell expressing one or more surface markers selected from the group consisting of CD 19, CD38, CD27, CD269, and MHCII, and not expressing CD20 and CD 138, and preferably refers to a CD38hlCD20lowcell
[0387] The term "plasma cell" or "plasma B cell" refers herein to a terminally differentiated B cells secreting large amounts of antibodies. Plasma cells do not express CD19 or CD20. In terms of phenotype, a plasma cell refers herein to a cell expressing one or more surface markers selected from the group consisting of CXCR4, CD27, CD38, CD 138, CD269, low CD 19, low MHCII, and low CD20, and preferably refers to a CD38hlCD20lowCD138+cell.
[0388] The term "B memory cell (Bmem)" refers to an antigen-experienced and long-lived population of B cells, which are quiescent but poised to quickly respond to antigens upon recall. In terms of phenotype, a memory B cell express one or more surface markers selected from thegroup consisting of CD19, CD20, CD40, CD27, CXCR4, CXCR5, and CXCR7. Memory B cells are CD231ow and do not express CD38.
[0389] The term "Tfh cell" refers herein to a T cell expressing one or more surface markers selected from the group consisting of ICOS, CXCR5, CD4, PD-1, and BCL-6, and not expressing CD45RA. In particular, a Tfh cell refers herein to an ICOS+CXCR5+CD4+BCL-6+ or ICOS+CXCR5+CD4+BCL-6+PD1+ or CXCR5 CD45RACD4+T cell, or combinations thereof A related aspect of the invention is a method of treating and / or preventing an immune disease in a subject, wherein the method comprises administering to the subject an effective amount of:
[0390] a multispecific binding protein according to the first aspect,
[0391] a nucleic acid or nucleic acids according to the second aspect,
[0392] a vector according to the third aspect,
[0393] a cell according to the fourth aspect, or
[0394] a pharmaceutical composition according to the fifth aspect,
[0395] thereby treating and / or preventing the immune disease in the subject.
[0396] In the above method, the multispecific binding protein according to the first aspect, the nucleic acid or nucleic acids according to the second aspect, the vector according to the third aspect, the cell according to the fourth aspect, or the pharmaceutical composition according to the fifth aspect are administered in effective amounts.
[0397] Anti-CXCR4 ABD
[0398] In an eighth aspect, the present invention relates to a mono- or multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH
[0399] (i) comprising CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3; and / or (ii) having at least 80% amino acid identity to SEQ ID NO: 3.
[0400] Some embodiments of the eighth aspect of the present invention relate to a mono or multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH comprising CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3. Some preferred embodiments of the eighth aspect of the present invention relate to a mono or multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH comprising CDR1 according to SEQ ID NO: 13, CDR2 according to SEQ ID NO: 14, and CDR3 according to SEQ ID NO: 15. In addition or alternatively, the eighthaspect of the present invention relates to a mono or multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 3.
[0401] One preferred embodiment of the present invention according to eighth aspect relates to a multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH comprising CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3. One further preferred embodiment of the present invention according to eighth aspect relates to a multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH comprising preferably CDR1 according to SEQ ID NO: 13, CDR2 according to SEQ ID NO: 14, and CDR3 according to SEQ ID NO: 15. In addition or alternatively, the eighth aspect of the present invention relates to a multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH having at least 80%, 90%, 95%, 98%, 99%, or 100% amino acid identity to SEQ ID NO: 3.
[0402] Definitions
[0403] To practice the present invention, unless otherwise indicated, conventional methods of chemistry, biochemistry, and recombinant DNA techniques are employed which are explained in the literature in the field (cf., e.g., Molecular Cloning: A Laboratory Manual, 2ndEdition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).
[0404] The specification uses a variety of terms and phrases, which have certain meanings as defined below. Preferred meanings are to be construed as preferred embodiments of the aspects of the invention described herein. As such, they and also further embodiments described in the following can be combined with any embodiment of the aspects of the invention and in particular any preferred embodiment of the aspects of the invention described above.
[0405] The term "about" when used in connection with a numerical value is meant to encompass numerical values within a range having a lower limit that is 5% smaller than the indicated numerical value and having an upper limit that is 5% larger than the indicated numerical value (each limit preferably 4%, 3%, 2% or 1% instead of 5%).
[0406] The term "extracellular domain" as used herein refers to a part of a molecule such as a protein that is facing the extracellular space of a cell and preferably is accessible from the outside of said cell, e.g., to antigen-binding domains or antibodies located outside the cell.
[0407] The terms "part" or "fragment" are used interchangeably herein and refer to a continuous element. For example, a part or fragment of an amino acid sequence or protein refers to acontinuous part of said sequence, i.e. a sequence which represents the amino acid sequence shortened at the N-terminus and / or C-terminus. A fragment shortened at the C-terminus (N-terminal fragment) is obtainable e.g. by translation of a truncated open reading frame that lacks the 3 '-end of the open reading frame. A fragment shortened at the N-terminus (C -terminal fragment) is obtainable e.g. by translation of a truncated open reading frame that lacks the 5'-end of the open reading frame, as long as the truncated open reading frame comprises a start codon that serves to initiate translation. A part or a fragment of an amino acid sequence or protein preferably preserves one or more functional properties of said amino acid sequence or protein, i.e. is a “functional part” or “functional fragment”. For example, a part or a fragment of an epitope or peptide is preferably immunologically equivalent to the epitope or peptide it is derived from. A part or fragment of a parental amino acid sequence preferably comprises a sequence of at least 4, in particular at least 6, at least 8, at least 12, at least 15, at least 20, at least 30, at least 50, or at least 100 consecutive amino acids of the parental amino acid sequence. Additionally or alternatively, a part or fragment of a parental amino acid sequence may comprises at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the parental amino acid sequence.
[0408] The term "immunoglobulin" relates to proteins of the immunoglobulin superfamily, preferably to antigen receptors such as antibodies or the B cell receptor (BCR). The immunoglobulins are characterized by a structural domain, i.e., the immunoglobulin domain, having a characteristic immunoglobulin (Ig) fold. The term immunoglobulin encompasses membrane bound immunoglobulins as well as soluble immunoglobulins. Soluble immunoglobulins are generally termed antibodies. Immunoglobulins generally comprise several chains, typically two identical heavy chains and two identical light chains which are linked via disulfide bonds. Each heavy chain has two regions, the constant region (CH), comprising 3-4 Ig domains, and the variable region (VH), comprising a single Ig domain. A light chain has one constant domain (CL) and one variable domain (VL). Immunoglobulin classes are also referred to as "isotypes" (for instance IgGl, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM) referring to the immunoglobulin class that is encoded by heavy chain constant region genes.
[0409] The term "antibody" refers herein to an immunoglobulin comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. The term "antibody" includes monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies and chimeric antibodies. The VH and VL domains can be subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs andfour FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk, 1987. J. Mol. Biol. 196, 901-917), and specifically for the VH: HFR1, HCDR1, HFR2, HCDR2, HFR3, HCDR3, HFR4, and for the VL: LFR1, LCDR1, LFR2, LCDR2, LFR3, LCDR3, LFR4. The variable regions of the heavy and light chains form a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0410] The term "antigen-binding fragment" or "antibody fragment" refers herein to one or more fragments of a binding agent such as an antibody that retain the ability to specifically bind to an antigen. An exemplary antigen-binding fragment is a scFv. It has been shown that the antigenbinding function of an antibody can be performed by fragments of a full-length antibody.
[0411] Antibodies, antigen-binding fragments, and antigen binding domains are herein defined by their target, e.g. "aCXCR4". This designation is for brevity, and such antibodies or antigen binding domains can also be termed “anti-<target>”, e.g. “anti-CXCR4”.
[0412] The term "anti-ICOSxanti-CXCR4" refers herein to a multispecific binding protein comprising an anti-ICOS ABD, an anti-CXCR4 ABD, and optionally a half-life increasing moiety, such as an anti-ALB ABD, irrespective of the type of linkage (i.e. genetic or conjugation) between the ABDs or between the ABDs and HLM. Other abbreviations are listed on pages 29 (last paragraph) and 30 (first paragraph).
[0413] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. Monoclonal antibodies may be produced by a hybridoma which includes a B cell obtained from a non-human animal, e.g., mouse, fused to an immortalized cell.
[0414] The term "antigen" refers herein to any substance, e.g. protein or peptide that is capable of being bound by an antibody, a B cell receptor and / or a T cell receptor. As used herein, an antigen refers to an antigen of CXCR4, ICOS or of a serum protein (for the half-life increasing ABD). An antigen comprises at least one epitope.
[0415] The term "epitope" refers herein to an antigenic determinant in a molecule, i.e., to a part or fragment of a molecule such as an antigen that is recognized by the immune system. For example, an epitope may be recognized by T cells, B cells or antibodies. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific chargecharacteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope of an antigen may include a continuous or discontinuous portion of the antigen and may be between about 5 and about 100, such as between about 5 and about 50, more preferably between about 8 and about 30, most preferably between about 10 and about 25 amino acids in length, for example, the epitope may be preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. In one embodiment, an epitope is between about 10 and about 25 amino acids in length. The epitope can be a T cell and / or a B cell epitope. A T cell epitope is an epitope that can be presented on the surface of an antigen-presenting cell, where it is bound to an MHC molecule. In humans, professional antigen-presenting cells are specialized to present MHC class II peptides, whereas most nucleated somatic cells present MHC class I peptides. T cell epitopes presented by MHC class I molecules are typically peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, e.g. 13-17 amino acids in length. A B cell epitope is an epitope that is recognised as three-dimensional structures on the surface of native antigens by B cells. Epitopes can be determined as described in "Epitope Mapping Protocols (Methods in Molecular Biology) by Glenn E. Morris ISBN-089603-375-9 and in "Epitope Mapping: A Practical Approach" Practical Approach Series, 248 by Olwyn M. R. Westwood, Frank C. Hay. Alternatively, epitopes can be predicted with in silico tools, e.g. the online B cell or T cell prediction tools of the IEDB Analysis Resource.
[0416] The term "binding" according to the invention preferably relates to a specific binding. The term "specific binding" as used herein means that a compound, e.g the first or second antigen binding domain or the half-life increasing antigen binding domain, binds stronger to a target such as the epitope for which it is specific compared to the binding to another (preferably any other) target. A compound binds stronger to a first target compared to a second target, if it binds to the first target with a dissociation constant (Ka) which is lower than the dissociation constant for the second target. Preferably the dissociation constant (Ka) for the target to which the compound binds specifically is more than 10-fold, preferably more than 20-fold, more preferably more than 50-fold, even more preferably more than 100-fold, 200-fold, 500-fold or 1000-fold lower than the dissociation constant (Ka) for the target to which the compound does not bind specifically.
[0417] Typically, antigen binding domains according to the invention bind with a sufficient binding affinity to their target, for example, with a Kd value of between 500 nM - 1 pM, i.e. 500 nM, 450 nM, 400nM, 350 nM, 300nM, 250 nM, 200 nM, 150 nM, lOOnM, 50 nM, 10 nM, 1 nM, 900 pM, 800 pM, 700 pM, 600 pM, 500 pM, 400 pM, 300 pM, 200 pM, 100 pM, 50 pM, 1 pM. This is also referred to herein as "substantial binding".As used herein, the term "Ka" (usually measured in "mol / L", sometimes abbreviated as "M") is intended to refer to the dissociation equilibrium constant of the particular interaction between a binding moiety (e.g. an antibody or antigen-binding fragment) and a target molecule (e.g. an antigen or epitope thereof such CXCR4 or ICOS).
[0418] Methods for determining binding affinities of compounds, i.e. for determining the dissociation constant Ka, are known to a person of ordinary skill in the art and can be selected for instance from the following methods known in the art: Surface Plasmon Resonance (SPR) based technology, Bio-layer interferometry (BLI), enzyme-linked immunosorbent assay (ELISA), flow cytometry, isothermal titration calorimetry (ITC), analytical ultracentrifugation, radioimmunoassay (RIA or IRMA), enhanced chemiluminescence (ECL), Scatchard analysis and / or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA) and sandwich competition assays. Typically, the dissociation constant Ka is determined at 20°C, 25°C, 30°C, or 37°C. If not specifically indicated otherwise, the Ka values recited herein are determined by surface plasmon resonance spectroscopy (Biacore™) at room temperature (25°C).
[0419] The competition between antibodies can be detected by a cross-blocking assay. For example, a competitive ELISA assay may be used as a cross-blocking assay. E.g., a target antigen may be coated on the wells of a microtiter plate and antigen-binding antibody and candidate competing test antibody may be added. The amount of the antigen-binding domain bound to the antigen in the well indirectly correlates with the binding ability of the candidate competing test antibody that competes therewith for binding to the same epitope. Specifically, the larger the affinity of the candidate competing test antibody is for the same epitope, the smaller the amount of the antigen-binding antibody bound to the antigen-coated well. The amount of the antigenbinding domain bound to the well can be measured by labeling the antibody with detectable or measurable labeling substances.
[0420] Alternatively, the multispecific binding protein activity can be characterized in terms of IC50 (inhibitory concentration 50) of a certain output, such as IgG production or IgM production by B cells co-cultured with Tfh cells. Thus, the IC50 may be calculated by measuring the inhibition activity of the multispecific antibody at increasing concentrations (e.g. Figure 3) and by using any method known in the art to plot that data in a curve and calculating the IC50. The IC50 for IgG production of the multispecific binding protein disclosed herein may be 1 mM or less, 0.5 mM or less, 0.1 mM or less, 0.05 mM or less, 0.05 pM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, or 0.39 or less, preferably is 1 nM or less, more preferably is 0.5 nM or less.. The IC50 for IgM productionof the multispecific binding protein disclosed herein may be 1 mM or less, 0.5 mM or less, 0.1 mM or less, 0.05 mM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, or 0.05 nM or less, preferably is 1 nM or less, more preferably is 0.5 nM or less.
[0421] The term "nucleic acid molecule" or "nucleic acid", as used herein, is intended to include deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules, e.g., in vitro transcribed RNA (IVT RNA). Nucleic acids, as used herein, include genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules. A nucleic can be employed for introduction into, i.e. transfection of, cells, for example, in the form of RNA which can be prepared by in vitro transcription from a DNA template. The RNA can moreover be modified before application by stabilizing sequences, capping, and polyadenylation. As used herein, the term "nucleic acid encoding" means that nucleic acid, if present in the appropriate environment, preferably within a cell, can be expressed to produce a protein or peptide it encodes. A nucleic acid, such as a nucleic acid expressing RNA and / or protein or peptide, and an expression control sequence are operably linked to one another, if they are covalently linked to one another in such a way that expression or transcription of said nucleic acid is under the control or under the influence of said expression control sequence. If the nucleic acid is to be translated into a functional protein, then, with an expression control sequence operably linked to a coding sequence, induction of said expression control sequence results in transcription of said nucleic acid, without causing a frame shift in the coding sequence or said coding sequence not being capable of being translated into the desired protein or peptide.
[0422] The term "expression control sequence" as used herein comprises promoters, ribosome binding sites, enhancers and other control elements which regulate transcription of a gene or translation of an mRNA. In particular embodiments, the expression control sequences can be regulated. The exact structure of expression control sequences may vary as a function of the species or cell type, but generally comprises 5'-untranscribed and 5'- and 3'-untranslated sequences (5'-UTR; 3'-UTR) which are involved in initiation of transcription and translation, respectively, such as TATA box, capping sequence, CAAT sequence, and the like. More specifically, 5'-untranscribed expression control sequences comprise a promoter region which includes a promoter sequence for transcriptional control of the operably linked nucleic acid. Expression control sequences may also comprise enhancer sequences or upstream activator sequences. Expression control sequences or regulatory sequences can be homologous or heterologous with respect to the nucleic acid. The term "promoter" or "promoter region" as used herein relates to a nucleic acid sequence which is located upstream (5') to the nucleic acid sequence being expressed and controlsexpression of the sequence by providing a recognition and binding site for RNA-polymerase. The "promoter region" may include further recognition and binding sites for further factors which are involved in the regulation of transcription of a gene. A promoter may control the transcription of a prokaryotic or eukaryotic gene. Furthermore, a promoter may be "inducible" and may initiate transcription in response to an inducing agent or may be "constitutive" if transcription is not controlled by an inducing agent. A gene which is under the control of an inducible promoter is not expressed or only expressed to a small extent if an inducing agent is absent. In the presence of the inducing agent the gene is switched on or the level of transcription is increased. This is mediated, in general, by binding of a specific transcription factor. Promoters which are preferred include promoters for SP6, T3 and T7 polymerase, human U6 RNA promoter, CMV promoter, and artificial hybrid promoters thereof (e.g., CMV) where a part or parts are fused to a part or parts of promoters of genes of other cellular proteins such as e.g., human GAPDH (glyceraldehyde-3-phosphate dehydrogenase), and including or not including (an) additional intron(s).
[0423] The term "vector" is used herein in its most general meaning and comprises any intermediary vehicle for a nucleic acid which enables said nucleic acid, for example, to be introduced into prokaryotic and / or eukaryotic cells and, where appropriate, to be integrated into a genome. Vectors of this kind are preferably replicated and / or expressed in the cells. Vectors comprise plasmid vectors, cosmid vectors, phage vectors such as lambda phage, liposomes, viral vectors such as adenovirus (Ad) vectors), adeno-associated virus (AAV) vectors, alphavirus vectors (e.g., Venezuelan equine encephalitis virus (VEE), sindbis virus (SIN), semliki forest virus (SFV), and VEE-SIN chimeras), herpes virus vectors, measles virus vectors, pox virus vectors (e.g., vaccinia virus, modified vaccinia virus Ankara (MV A), NYVAC (derived from the Copenhagen strain of vaccinia), and avipox vectors: canarypox (ALVAC) and fowlpox (FPV) vectors), and vesicular stomatitis virus vectors, or virus like particles. As used herein, the term "virus-like particle" or "VLP" refers to a non-replicating, empty viral shell. VLPs are generally composed of one or more viral proteins, such as, but not limited to those proteins referred to as capsid, coat, shell, surface and / or envelope proteins. They contain functional viral proteins responsible for cell penetration by the virus, which ensures efficient cell entry. Methods for producing particular VLPs are known in the art. Said vectors include expression as well as cloning vectors. Expression vectors comprise plasmids as well as viral vectors and generally contain a desired coding sequence and appropriate DNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g., bacteria, yeast, plant, insect, or mammal) or in in vitro expression systems. Cloning vectors are generally used to engineer and amplify a certain desired DNA fragment and may lack functional sequences needed for expressionof the desired DNA fragments. The term "plasmid" as used herein generally relates to a construct of extrachromosomal genetic material, usually a circular DNA duplex, which can replicate independently of chromosomal DNA.
[0424] The term "transfection" is used herein generally to mean the delivery and introduction of a nucleic acid into a cell in such a way that the nucleic acid retains its function within the cell. Transfection methods are preferably applied to cells in vitro. The term includes the more specific meaning of delivery and introduction of expressible nucleic acid into a cell such that the cell is rendered capable of expressing that nucleic acid. The term expression means any manifestation of the functional presence of the nucleic acid within a cell, including both transient expression and stable expression.
[0425] The term "sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions.
[0426] The term "identity" or "identical" in the context of polynucleotide, polypeptide or protein sequences refers herein to the number of residues in the two sequences that are identical when aligned for maximum correspondence. Specifically, the percent sequence identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequence and multiplied by 100. Alignment tools that can be used to align two sequences are well known to the person skilled in the art and can, for example, be obtained on the World Wide Web, e.g., Clustal Omega (http: / / www.ebi.ac.uk / Tools / msa / clustalo / ) for polypeptide alignments or MUSCLE (http: / / www.ebi.ac.uk / Tools / msa / muscle / ) or MAFFT (http: / / www.ebi.ac.uk / Tools / msa / mafft / ) for polynucleotide alignments or WATER (http: / / www.ebi.ac.uk / Tools / psa / emboss_water / ) for polynucleotide and polypeptide alignments. The alignments between two sequences may be carried out using default parameters settings, e.g., for MAFFT preferably: Matrix: Blosum62, Gap Open 1.53, Gap Extend 0.123, for WATER polynucleotides preferably: MATRIX: DNAFULL, Gap Open: 10.0, Gap Extend 0.5 and for WATER polypeptides preferably MATRIX: BLOSUM62, Gap Open: 10.0, Gap Extend: 0.5. Those skilled in the art understand that it may be necessary to introduce gaps in either sequence to produce a satisfactory alignment. The "best sequence alignment" is defined as the alignment that produces the largest number of aligned identical residues while having a minimal number of gaps. Preferably, it is a global alignment, which includes every residue in every sequence in the alignment.
[0427] The term "variant" refers, with respect to a polypeptide, generally to a modified version of the polypeptide, e.g., a mutation, so one or more amino acids of the polypeptide may be deleted, inserted, modified and / or substituted. Generally, the variant is a functional variant, meaning thatit preserves the function of the parent polypeptide. More specific functions are defined herein and have precedence over the general definition. A "mutation" or "amino acid mutation" can be an amino acid substitution, deletion and / or insertion ("and" may apply if there is more than one mutation). Preferably, it is a substitution (i.e., a conservative or non-conservative amino acid substitution), more preferably a conservative amino acid substitution. In some embodiments, a substitution also includes the exchange of a naturally occurring amino acid with a not naturally occurring amino acid. A conservative substitution comprises the substitution of an amino acid with another amino acid having a chemical property similar to the amino acid that is substituted. Preferably, the conservative substitution is a substitution selected from the group consisting of:
[0428] (i) a substitution of a basic amino acid with another, different basic amino acid;
[0429] (ii) a substitution of an acidic amino acid with another, different acidic amino acid;
[0430] (iii) a substitution of an aromatic amino acid with another, different aromatic amino acid; (iv) a substitution of a non-polar, aliphatic amino acid with another, different non-polar, aliphatic amino acid; and
[0431] (v) a substitution of a polar, uncharged amino acid with another, different polar, uncharged amino acid.
[0432] A basic amino acid is preferably selected from the group consisting of arginine, histidine, and lysine. An acidic amino acid is preferably aspartate or glutamate. An aromatic amino acid is preferably selected from the group consisting of phenylalanine, tyrosine and tryptophane. An aliphatic uncharged amino acid is preferably selected from the group consisting of glycine, alanine, valine, leucine, and isoleucine. A hydrophilic uncharged amino acid is preferably selected from the group consisting of serine, threonine, asparagine, and glutamine. A non-polar uncharged amino acid is preferably selected from the group consisting of cysteine, methionine, proline. In contrast to a conservative amino acid substitution, a non-conservative amino acid substitution is the exchange of one amino acid with any amino acid that does not fall under the above-outlined conservative substitutions (i) through (v).
[0433] Amino acids of a protein may also be modified, e.g., chemically modified. For example, the side chain or a free amino or carboxy-terminus of an amino acid of the protein or polypeptide may be modified by e.g., glycosylation, amidation, phosphorylation, ubiquitination, etc. The chemical modification can also take place in vivo, e.g., in a host-cell, as is well known in the art. For example, a suitable chemical modification motif, e.g., glycosylation sequence motif present in the amino acid sequence of the protein will cause the protein to be glycosylated. Unless a modification leads to a change in identity of a modified amino acid (e.g., a substitution or deletion),a modified polypeptide is within the scope of polypeptide as mentioned with respect to a certain SEQ ID NO, i.e., it is not a variant as defined herein.
[0434] Preferably, the degree of identity between a given amino acid sequence and an amino acid sequence which is a variant of said given amino acid sequence will be at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of identity is given preferably for an amino acid region which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of identity is given preferably for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids, in some embodiments, continuous amino acids. In some embodiments, the degree of similarity or identity is given for the entire length of the reference amino acid sequence.
[0435] The amino acid sequence variants described herein may readily be prepared by the skilled person, for example, by recombinant DNA manipulation or with the aid of known peptide synthesis techniques such as, for example, by solid phase synthesis and similar methods. The manipulation of DNA sequences for preparing peptides or proteins having substitutions, additions, insertions or deletions, is described in detail in Sambrook etal. (1989), for example.
[0436] The term "variant" refers, with respect to a polynucleotide, generally to a modified version of the polynucleotide, e.g., a mutation, so one or more nucleotides of the polynucleotide may be deleted, inserted, modified and / or substituted. Generally, the variant is a functional variant, meaning that it preserves the function of the parent polynucleotide, such as specific binding ability to the target (e.g. CXCR4 or ICOS). More specific functions are defined herein and have precedence over the general definition. A "mutation" can be a nucleotide substitution, deletion and / or insertion ("and" may apply if there is more than one mutation). Preferably, it is a substitution, more preferably it causes an amino acid substitution, most preferably a conservative amino acid substitution.
[0437] Preferably the degree of identity between a given nucleic acid sequence and a nucleic acid sequence which is a variant of said given nucleic acid sequence will be at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of identity is given preferably for a nucleic acid region which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of theentire length of the reference nucleic acid sequence. For example, if the reference nucleic acid sequence consists of 200 nucleic acids, the degree of identity is given preferably for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 nucleic acids, in some embodiments, continuous nucleic acids. In some embodiments, the degree of similarity or identity is given for the entire length of the reference a nucleic acid sequence.
[0438] The term "functional variant" of an amino acid sequence includes "functional" fragments of said amino acid sequence. Characteristics of functional variants, e.g., binding characteristics, can be analysed by known methods, e.g., using an ELISA-assay.
[0439] The term "recombinant" refers herein in particular to a virus that is modified to comprise a heterologous polynucleotide sequence in its genome.
[0440] By "treat" is meant herein to administer a multispecific binding protein according to the first aspect to a subject in order to prevent or eliminate a disease; arrest or slow a disease in a subject; inhibit or slow the development of a new disease in a subject; decrease the frequency or severity of symptoms and / or recurrences in a subject who currently has or who previously has had a disease; and / or prolong, i.e. increase the lifespan of the subject, wherein the disease is preferably an immune disease, more preferably an autoimmune disease.
[0441] In particular, the term "treatment of a disease" includes curing, shortening the duration, ameliorating, preventing, slowing down or inhibiting progression or worsening, or preventing or delaying the onset of a disease or the symptoms thereof.
[0442] ***
[0443] The invention is described by way of the following examples that are to be construed as merely illustrative and not limitative of the scope of the invention.
[0444] EXAMPLES
[0445] Example 1: IgM and IgG inhibitory activity of an anti-ICOSxanti-CXCR4 bispecific binding protein in a Tfh / B cell co-culture system.
[0446] The ability of purified, monospecific or bi-specific binding proteins to inhibit the activity of primary B cells in co-culture with Tfh cells was assessed by measuring secretion of IgM and IgG after SEB-costimulation. The binding proteins were designed with the sequences indicated below and with different functional building blocks connected by flexible 9GS Gly / Ser linkers (GGGGSGGGS). Within the context of this example, anti-CXCR4 VHH fused to anti-ALB and anti-ICOS VHH fused to SpyTag should be considered as mono-specific, while alCOS-aALB-aCXCR4 has bi-specific functionality. Mono-specific and bi-specific binding proteins were subsequently expressed in Pichia pastoris and purified using protein A affinity chromatography.
[0447] Briefly, human B cells were isolated from frozen PBMC from six different healthy donors using CD 19 microbeads (Miltenyi). Autologous memory CD4+T cells were isolated from the B cell depleted PBMC via negative selection (EasySep Human Memory CD4+T Cell Enrichment Kit. StemCell) and subsequently follicular T helper cells (Tfh) were isolated from this fraction via FACS sorting as CXCR5 CD45RACD4+T cells.
[0448] Isolated B cells and Tfh cells were co-cultured at a 1 : 1 ratio (10,000 cells of each) in RPMI medium supplemented with 10% heat-inactivated Fetal Bovine Serum, ImM sodium pyruvate, non-essential amino acids, 50pM P-mercaptoethanol, penicillin / streptomycin in 96 well roundbottom plates in presence of 10 ng / ml Staphylococcal Enterotoxin B (SEB) and 200nM of the test proteins aCXCR4-aALB (SEQ ID NO: 6), alCOS-SpyTag (SEQ ID NO: 8), and alCOS-aALB-aCXCR4 (SEQ ID NO: 9). After 10 days of co-culture, cell supernatants were collected and IgG and IgM concentrations analyzed by ELISA (Invitrogen).
[0449] The obtained results (Figure 1) clearly indicated a lack of modulation of IgG and IgM secretion in supernatants of cells treated with monospecific binding proteins blocking either CXCR4 (aCXCR4-aALB) or ICOS (alCOS-SpyTag), and a clear inhibition of IgG and IgM levels with the aICOS-aALB-aCXCR4 bispecific binding protein.
[0450] Example 2: IgM and IgG inhibitory activity of the anti-ICOS*anti-CXCR4 bispecific binding protein requires a bispecific construct and is not due to the combination of CXCR4 and ICOS blockade.
[0451] The ability of aICOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein versus the individual monospecific controls (alone or in combination) to inhibit the activity of primary B cells in a co-culture with primary Tfh cells was assessed by measuring secretion of IgM and IgG after SEB co-stimulation.
[0452] Briefly, IgG and IgM concentrations were analyzed in the supernatants of co-cultures of primary human B cells and Tfh isolated from two different donors and treated as described in Example 1.
[0453] The results showed that aICOS-aALB-aCXCR4 protein induced a remarkable decrease in both IgG and IgM secretion and accumulation in the co-culture supernatant while the co-addition (combo) of aCXCR4-aALB and alCOS-SpyTag had no effect (Figure 2). As illustrated in theprevious example, treatment with the monospecific proteins in isolation did not induce any decrease in IgG and IgM secretion and accumulation in the co-culture supernatant.
[0454] Example 3: IgG and IgM secretion by B cells needs Tfh costimulation.
[0455] The ability of aICOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein to inhibit secretion of IgM and IgG was analysed in B cells co-cultured with Tfh cells versus B cells cocultured with not-Tfh cells.
[0456] Briefly, IgG and IgM concentrations were analyzed in the supernatants of co-cultures of primary human B cells and Tfh or non-Tfh cells, which were isolated from two different donors and treated as described in Example 1. Non-Tfh cells were isolated by FACS sorting as CXCR5' CD45RA CD4+CD3+T cells.
[0457] Results illustrated in Figure 3 indicate that IgM and IgG secretion and accumulation in the supernatant of the co-culture require B cell stimulation by Tfh cells. Non-Tfh cells (CXCR5-memory CD4 cells) did not promote the secretion and accumulation of IgG and IgM in the coculture supernatant.
[0458] Notably, bispecific aICOS-aALB-aCXCR4 potently inhibited the IgM and IgG secretion and accumulation in the supernatant of the Tfh / B cell co-culture from both donors with IC50s ranging between 3.85E-10 (donor 783920) and 3.87E-10 M (donor 783921) for IgM inhibition and between 3.74E-11 (donor 783920) and 3.46E-10 M (donor 783921) for IgG inhibition.
[0459] Example 4: Blockade by bispecific anti-ICOS*anti-CXCR4 inhibits proliferation of Tfh cells, survival of B cells, and formation of plasmablasts and plasma cells in Tfh / B cell cocultures.
[0460] Briefly, Tfh cells, B cells, plasmablasts and plasma cells were quantified in the supernatants of co-cultures of primary human B cells and Tfh cells and treated as described in Example 1. This experiment was performed using cells from two different donors. After 10 days of co-culture, cells were collected and analyzed by flow cytometry using the following markers: Tfh cells: CXCR5 CD45RA CD4+, B cells: CD19+, plasmablasts: CD38hiCD20low, and plasma cells: CD38hiCD20lowCD138+.
[0461] Figure 4 shows that after ten days of co-culture in the presence of B cells and SEB costimulation, the CD4+T cell population significantly increased by a factor of two to three times in the two donors (20,000-30,000 cells detected in aRSV-aALB (SEQ ID NO: 10) and blank conditions versus the 10,000 cells seeded at the start of the co-culture). In comparison, a ICOS-aALB-aCXCR4 bispecific protein (SEQ ID NO: 9) inhibited T cell proliferation and made final T cell counts comparable to the number of seeded cells. Interestingly, the co-addition of anti-CXCR4 and anti-ICOS proteins (aCXCR4-aALB, SEQ ID NO: 6, and alCOS-SpyTag, SEQ ID NO: 8, respectively) or exposure to the individual mono-specific proteins had no effect.
[0462] In addition, the B cell population was stable showing a slight decrease of only 20-30% compared to the number of seeded cells. In comparison, aICOS-aALB-aCXCR4 prevented Tfh support to B cells in these conditions and resulted in a significant decrease in B cell number after 10 days of co-culture. Of interest, the proportion of plasmablasts and plasma cells originating from naive B cells included in the co-culture is also decreased by exposure to aICOS-aALB-aCXCR4, suggesting that the simultaneous blockade of these two targets may prevent both B cell survival and differentiation to plasmablasts and plasma cells induced by Tfh.
[0463] Example 5: anti-ICOS xanti-CXCR4 bispecific binding protein inhibits antigenspecific IgG responses to Fluzone in a MIMIC antigen-recall assay.
[0464] The ability of purified, monospecific or bi-specific binding proteins to inhibit antigen-specific IgG responses and the effect of these proteins on influenza hemagglutinin (HA) specific B cell responses was evaluated in a MIMIC (Modular IMmune In vitro Construct) Recall assay using Fluzone Quadrivalent Influenza Vaccine (QIV).
[0465] aICOS-aALB-aCXCR4 protein (SEQ ID NOs: 9, 50) was generated by genetic fusion as described in Example 1, while other molecules evaluated in this example were generated by bioconjugation. Bioconjugated control (aRSV-SpyTag / aRSV-SpyCatcher), monospecific (alCOS-SpyTag / aRSV-SpyCatcher, aCXCR4-SpyTag / aRSV-SpyCatcher) and bispecific (aICOS-SpyTag / aCXCR4-SpyCatcher) proteins were generated by reacting a 12 pM concentration of VHH-SpyCatcher with a 8 pM concentration of VHH-SpyTag at room temperature. The excess of unconjugated VHH-SpyCatcher was eventually removed with SpyTag-coated biotin beads.
[0466] A MIMIC® transwell peripheral tissue equivalent module was used to generate antigen presenting cells (APCs) as previously described (Dauner et al., 2017. Vaccine, Vol. 35, Issue 41: p5487-5494). Briefly, pre-vaccination donor PBMCs were applied to transwells containing confluent endothelial cells (EA.hy 926, ATCC) in a 24-well plate, followed by stimulation for 24 h with Fluzone QIV or nothing. The dose used was determined to be the optimal concentration of QIV for eliciting a detectable immune response via dose titration studies (data not shown). Differentiated APCs were harvested from the lower transwell chamber 48 h after PBMC application. Autologous CD4+T and CD19+B cells were isolated from PBMCs using magnetic enrichment kits (Stemcell Technologies), after which the B cells were cultured with QIV or leftuntreated. Pre-treated APCs were co-cultured with autologous CD4+T cells and the pre-treated CD19+B cells for 14 days. Culture supernatants were collected for detection of total and functional anti -hemagglutinin IgG antibodies to Hl, H3 or B strains via Antibody Forensics, a multiplexed, bead-based ELISA assay that measures total IgG. APCs, CD4+T, and CD19+B cells were all pretreated with mono- or bi-specific proteins binding to ICOS and / or CXCR4 for 2hr at 200nM prior to Fluzone QIV treatment.
[0467] Combined IgG responses to the Hl, H3 and B strains were used as a primary readout. Figure 5 reports on the combined levels of IgG. To minimize the impact of donor-to-donor variability, only donors’ samples showing a >1.5 fold IgG increase following exposure to Fluzone were included in the analysis (Responders) and IgG levels were expressed as Stimulation Index ratio (values from Fluzone-only treated wells versus wells treated with Fluzone and treatments with mono- and bispecific protein). In these conditions, neither the monospecific alCOS-SpyTag / aRSV-SpyCatcher nor the monospecific aCXCR4-SpyTag / aRSV-SpyCatcher induced marked modulations of Stimulation Index ratio and showed a modulation profile comparable to the aRSV-SpyTag / aRSV-SpyCatcher control. In comparison, both bispecific aCXCR4-SpyTag / alCOS-SpyCatcher and aICOS-aALB-aCXCR4 were associated with a greater than 3-fold decrease in IgG levels stimulated by Fluzone QIV treatment.
[0468] Example 6: Low cytokine release following culture of aICOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein with PBMCs from both healthy donors and donors with Sjogren's syndrome.
[0469] The ability of aICOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein to cause cytokine release when incubated with PBMCs from Sjogren's syndrome donors and healthy donors was assessed.
[0470] Briefly, frozen PBMCs from 5 Sjogren's syndrome donors and 5 healthy donors were thawed and cultured overnight in RPMI medium supplemented with 10% heat-inactivated Fetal Bovine Serum, and penicillin / streptomycin in 96 well round-bottom plates in presence of alCOS-aALB-aCXCR4 (SEQ ID NO: 9) ranging from 0.001 nM to 100 nM or controls.
[0471] Controls included anti-CD3 + anti-CD28 (at 1 pg / ml each), OKT3 (at 1 pg / ml), a monoclonal antibody that binds CD3 and activates T cells, and a Teplizumab-like monoclonal antibody (at 100 nM) that also binds to CD3. An ICOS bivalent Nanobody® compound (consisting of two linked VHH’s each specifically binding to ICOS) was also used at a concentration of 100 nM. Following overnight culture, cell supernatants were collected and IFNy, IL-6, TNFa, GM-CSF, IL-17A, and IL-10 concentrations were analyzed with a multiplex cytokine assay (Meso Scale Discovery). Data are expressed as a fold change compared to the media alone control.
[0472] The results indicate that aICOS-aALB-aCXCR4 (SEQ ID NO: 9) bispecific binding protein induced little to no cytokine release at concentrations ranging from 0.001 nM to 100 nM in cultures of PBMC isolated from healthy donors or donors with Sjogren's syndrome (Figure 6 A-F).
[0473] Example 7: Effect of CXCR4-ICOS bispecific combination in a Tfh / B cell reverse synapse model.
[0474] The ability of purified, bi-specific ISVD molecules to impact the formation of T-B collaboration was evaluated in a supported lipid bilayer experiment measuring ICAM, MHC-II and the bi-specific ISVD localization on a T-cell mimicking membrane following the interaction with activated B cells.
[0475] Briefly, human B cells were isolated from frozen PBMCs from healthy donors by negative selection using the EasySep™ Human Naive B Cell Isolation Kit (STEM CELL Technology) and activated with 1 pg / mL R484 (InvivoGen), 5 pg / mL a-CD40 (BioLegend), 3 pg / mL CpG-A (InvivoGen), and 100 ng / mL LPS (Merck Life Science) for 48 hours.
[0476] T cell mimicking supported lipid bilayers were formed on glass slides using lipid mixtures containing 2% NTA lipids and 0.0625% CapBio lipids (Avanti Polar Lipids). Fluorescently labelled ICAM1 (AF405, 200 molecules / pm2), anti-MHC-II Fab (AF488, 30 molecules / pm2), and unlabelled ICOS (100 molecules / pm2) were included in the supported lipid bilayer and exposed to activated B cells described above and aICOS-aALB-aCXCR4 (SEQ ID NO: 9) compound or the non-binding RSV control.
[0477] Cells were fixed with 4% PFA for 10 minutes at 37°C and washed samples were subsequently incubated with Alexa Fluor 647-conjugated anti-ISVD antibody. Images were acquired using an Olympus Total Internal Reflection Fluorescence (TIRF) microscope with appropriate acquisition settings and imaging parameters.
[0478] Figure 7 represents the distribution of the different markers and bright field microscopy images of cells exposed to aICOS-aALB-aCXCR4 (SEQ ID NO: 9) or to an RSV control ISDV.
[0479] The B cells formed contacts with the SLB using the uropod (Uro) and cell body. The cell body attached through LFA-l-ICAM-1 interactions, whereas the uropod attached through the anti-MHC class II and the bispecific aICOS-aALB-aCXCR4. Interestingly, aICOS-aALB-aCXCR4 (SEQ ID NO: 9) binding segregated from the anti-MHC class II and tended to increase the area ofanti-MHC II signal compared to the pattern of tight clustering of anti-MHC II seen in the nonbinding RSV control.
Claims
CLAIMS1. A multispecific binding protein comprising:(a) a first antigen-binding domain (ABD) specifically binding to an extracellular domain of ICOS; and(b) a second ABD specifically binding to an extracellular domain of CXCR4.
2. The multispecific binding protein of claim 1, wherein:(a-i) the first ABD is an antagonist of ICOS;(a-ii) the first ABD binds to an epitope of the extracellular domain of ICOS within amino acids 21-140 of SEQ IDNO: 2;(b-i) the second ABD is an antagonist of CXCR4 or a non-antagonist of CXCR4, preferably the first ABD is an antagonist of CXCR4; and / or(b-ii) the second ABD binds to an epitope of the extracellular domain of CXCR4 within amino acids 1-38, 100-110, 175-195, and / or 262-282 of SEQ ID NO: 1.
3. The multispecific binding protein of claim 1 or 2, wherein the first ABD and / or the second ABD comprise(s) a mAb, heavy chain antibody (HCAb), immunoglobulin single variable domain (ISVD), preferably a VH, VHH, humanized VHHs, single domain antibody (sdAb), or diabody (dAb); an IgG, a scFv, scFv?, scFv4, a Fv, Fab, Fab', F(ab')2, double variable domain (DVD), triple variable domain (TVD), or a single chain antibody-like protein scaffold, in particular an anticalin, DARPins, affibody, affimer, avimer, neutrophil gelatinase-associated lipocalin (NGAL) or evasin.
4. The multispecific binding protein of any of claims 1 to 3, wherein:(a) the first ABD comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 4, preferably CDR1 according to SEQ ID NO: 20, CDR2 according to SEQ ID NO: 21, and CDR3 according to SEQ ID NO:22; and / or(b) the second ABD comprises CDR1, CDR2 and CDR3 as comprised in SEQ ID NO:3, preferably CDR1 according to SEQ ID NO: 13, CDR2 according to SEQ ID NO: 14, and CDR3 according to SEQ ID NO: 15.
5. The multispecific binding protein of any of claims 1 to 4, wherein:(i) the first and / or the second ABD comprise(s) a VHH, and / or(ii) the first ABD is located C-terminally of the second ABD.
6. The multispecific binding protein of any of claims 1 to 5, wherein:(a) the first ABD comprises a VHH sequence having at least 80% amino acid identity to SEQ ID NO: 4; and / or(b) the second ABD comprises a VHH sequence having at least 80% amino acid identity to SEQ ID NO: 3.
7. The multispecific binding protein of any one of claims 1 to 6, wherein the binding protein further comprises a half-life increasing moiety, preferably selected from the group consisting of a polyethylene glycol (PEG), an antibody Fc portion, and an ABD with binding specificity to a serum protein.
8. The multispecific binding protein of any one of claims 1 to 7, wherein the first ABD and the second ABD are covalently linked directly or indirectly by a linker, wherein the linker preferably comprises a half-life increasing moiety and optionally one or more peptide linkers.
9. The multispecific binding protein of any one of claims 1 to 8, wherein the multispecific binding protein is a fusion protein, wherein the multispecific binding protein preferably comprises an amino acid sequence having at least 80% amino acid identity to SEQ ID NO: 9, or wherein the multispecific binding protein is a conjugate, wherein the first ABD and the second ABD are preferably linked by their C-termini.
10. A nucleic acid or nucleic acids encoding the multispecific binding protein of any one of claims 1 to 10, or a vector comprising said nucleic acid or nucleic acids.
11. A cell comprising the nucleic acid or nucleic acids or the vector of claim 10.
12. A pharmaceutical composition comprising the multispecific binding protein of any one of claims 1 to 9, the nucleic acid or nucleic acids or the vector of claim 10, or the cell of claim 11, and at least one pharmaceutically acceptable carrier, diluent, excipient and / or adjuvant.5713. A multi specific binding protein according to any one of claims 1 to 9, nucleic acid or vector according to claim 10, cell according to claim 11, or pharmaceutical composition according to claim 12 for use in medicine.
14. A multispecific binding protein according to any one of claims 1 to 9, nucleic acid or vector according to claim 10, cell according to claim 11, or pharmaceutical composition according to claim 12 for use in a method of treating and / or preventing an immune disease, preferably an auto-immune disease in a subject.
15. A mono or multispecific binding protein comprising an ABD specifically binding to the extracellular domain of CXCR4 comprising a VHH:(i) comprising CDR1, CDR2 and CDR3 as comprised in SEQ ID NO: 3, preferably CDR1 according to SEQ ID NO: 13, CDR2 according to SEQ ID NO: 14, and CDR3 according to SEQ ID NO: 15; and / or(ii) having at least 80% amino acid identity to SEQ ID NO: 3.58
